Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 559 articles:
HTML format
Text format



Single Articles


    November 2019
  1. LAWTON M, Baig F, Toulson G, Morovat A, et al
    Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort.
    Mov Disord. 2019 Nov 6. doi: 10.1002/mds.27888.
    PubMed     Text format     Abstract available


  2. PETRILLO S, Schirinzi T, Di Lazzaro G, D'Amico J, et al
    Systemic activation of Nrf2 pathway in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27878.
    PubMed     Text format     Abstract available


  3. HAQUE ME, Akther M, Jakaria M, Kim IS, et al
    Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27874.
    PubMed     Text format     Abstract available


    October 2019
  4. GILAT M, Coeytaux Jackson A, Marshall NS, Hammond D, et al
    Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Randomised Controlled Trial.
    Mov Disord. 2019 Oct 31. doi: 10.1002/mds.27886.
    PubMed     Text format     Abstract available


  5. LERCHE S, Wurster I, Roeben B, Zimmermann M, et al
    Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles.
    Mov Disord. 2019 Oct 30. doi: 10.1002/mds.27884.
    PubMed     Text format     Abstract available


  6. BANDRES-CIGA S, Ahmed S, Sabir MS, Blauwendraat C, et al
    The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight.
    Mov Disord. 2019 Oct 29. doi: 10.1002/mds.27864.
    PubMed     Text format     Abstract available


  7. NOYCE AJ, Bandres-Ciga S, Kim J, Heilbron K, et al
    The Parkinson's Disease Mendelian Randomization Research Portal.
    Mov Disord. 2019 Oct 28. doi: 10.1002/mds.27873.
    PubMed     Text format     Abstract available


  8. HAYAKAWA H, Nakatani R, Ikenaka K, Aguirre C, et al
    Structurally distinct alpha-synuclein fibrils induce robust parkinsonian pathology.
    Mov Disord. 2019 Oct 23. doi: 10.1002/mds.27887.
    PubMed     Text format     Abstract available


  9. PRETEGIANI E, Vanegas-Arroyave N, FitzGibbon EJ, Hallett M, et al
    Evidence From Parkinson's Disease That the Superior Colliculus Couples Action and Perception.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27861.
    PubMed     Text format     Abstract available


  10. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27876.
    PubMed     Text format     Abstract available


  11. MORALES-BRICENO H, Mahant N, Ha AD, Chang FCF, et al
    Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27883.
    PubMed     Text format    


  12. KOLMANCIC K, Perellon-Alfonso R, Pirtosek Z, Rothwell JC, et al
    Sex differences in Parkinson's disease: A transcranial magnetic stimulation study.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27870.
    PubMed     Text format     Abstract available


  13. VAN DER VEEN S, Zutt R, Klein C, Marras C, et al
    Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27828.
    PubMed     Text format     Abstract available


  14. SACHELI MA, Neva JL, Lakhani B, Murray DK, et al
    Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27865.
    PubMed     Text format     Abstract available



  15. Abstracts of the 2019 International Congress of the Parkinson's Disease and Movement Disorders(R).
    Mov Disord. 2019;34 Suppl 2:S1-S930.
    PubMed     Text format    


    September 2019
  16. BOUTHOUR W, Bereau M, Kibleur A, Zacharia A, et al
    Dyskinesia-inducing lead contacts optimize outcome of subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27853.
    PubMed     Text format     Abstract available


  17. DAYAL V, Grover T, Tripoliti E, Milabo C, et al
    Short Versus Conventional Pulse-Width Deep Brain Stimulation in Parkinson's Disease: A Randomized Crossover Comparison.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27863.
    PubMed     Text format     Abstract available


  18. LEE PC, Artaud F, Cormier-Dequaire F, Rascol O, et al
    Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2019 Sep 13. doi: 10.1002/mds.27854.
    PubMed     Text format     Abstract available


  19. IWAKI H, Blauwendraat C, Leonard HL, Kim JJ, et al
    Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.
    Mov Disord. 2019 Sep 10. doi: 10.1002/mds.27845.
    PubMed     Text format     Abstract available


  20. SU TH, Yang HC, Tseng TC, Chou SW, et al
    Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism.
    Mov Disord. 2019 Sep 10. doi: 10.1002/mds.27848.
    PubMed     Text format     Abstract available


  21. WONG YC, Luk K, Purtell K, Burke Nanni S, et al
    Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27823.
    PubMed     Text format     Abstract available


  22. POTASHKIN J, Huang X, Becker C, Chen H, et al
    Understanding the links between cardiovascular disease and Parkinson's disease.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27836.
    PubMed     Text format     Abstract available


  23. AQUINO CC, Duffley G, Hedges DM, Vorwerk J, et al
    Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27839.
    PubMed     Text format     Abstract available


  24. MOHANA SUNDARAM S, Garg P
    The gut-brain axis in Parkinson's disease: A focus on the transport of alpha-Synuclein.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27842.
    PubMed     Text format    


  25. FISHMAN P, Lipsman N
    Focused ultrasound as an evolving therapy for Parkinson's disease.
    Mov Disord. 2019;34:1241-1242.
    PubMed     Text format    


    August 2019
  26. NISSEN SK, Shrivastava K, Schulte C, Otzen DE, et al
    Alterations in Blood Monocyte Functions in Parkinson's Disease.
    Mov Disord. 2019 Aug 26. doi: 10.1002/mds.27815.
    PubMed     Text format     Abstract available


  27. SILVA DE LIMA AL, Smits T, Darweesh SKL, Valenti G, et al
    Home-based monitoring of falls using wearable sensors in Parkinson's disease.
    Mov Disord. 2019 Aug 26. doi: 10.1002/mds.27830.
    PubMed     Text format     Abstract available


  28. TERROBA-CHAMBI C, Bruno V, Millar-Vernetti P, Bruce D, et al
    Design and validation of a new instrument to assess fear of falling in Parkinson's disease.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27820.
    PubMed     Text format     Abstract available


  29. GAL O, Polakova K, Hoskovcova M, Tomandl J, et al
    Pavement patterns can be designed to improve gait in Parkinson's disease patients.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27831.
    PubMed     Text format     Abstract available


  30. STUART S, Lawson RA, Yarnall AJ, Nell J, et al
    Pro-Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE-PD.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27813.
    PubMed     Text format     Abstract available


  31. GORGES M, Kuntz B, Del Tredici K, Schmidt DG, et al
    Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson's disease.
    Mov Disord. 2019 Aug 21. doi: 10.1002/mds.27814.
    PubMed     Text format     Abstract available


  32. DE LA CASA-FAGES B, Fernandez-Eulate G, Gamez J, Barahona-Hernando R, et al
    Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism.
    Mov Disord. 2019 Aug 21. doi: 10.1002/mds.27812.
    PubMed     Text format     Abstract available


  33. FOFFANI G, Trigo-Damas I, Pineda-Pardo JA, Blesa J, et al
    Focused ultrasound in Parkinson's disease: A twofold path toward disease modification.
    Mov Disord. 2019 Aug 14. doi: 10.1002/mds.27805.
    PubMed     Text format     Abstract available


  34. HEINZEL S, Berg D, Gasser T, Chen H, et al
    Update of the MDS research criteria for prodromal Parkinson's disease.
    Mov Disord. 2019 Aug 14. doi: 10.1002/mds.27802.
    PubMed     Text format     Abstract available


    July 2019
  35. MOLLENHAUER B, Caspell-Garcia CJ, Coffey CS, Taylor P, et al
    Longitudinal analyses of cerebrospinal fluid alpha-Synuclein in prodromal and early Parkinson's disease.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27806.
    PubMed     Text format     Abstract available


  36. HAQ IU, Snively BM, Sweadner KJ, Suerken CK, et al
    Revising rapid-onset dystonia-parkinsonism: Broadening indications for ATP1A3 testing.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27801.
    PubMed     Text format     Abstract available


  37. KARAKATSANI ME, Blesa J, Konofagou EE
    Blood-brain barrier opening with focused ultrasound in experimental models of Parkinson's disease.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27804.
    PubMed     Text format     Abstract available


  38. OZTURK M, Abosch A, Francis D, Wu J, et al
    Distinct subthalamic coupling in the ON state describes motor performance in Parkinson's disease.
    Mov Disord. 2019 Jul 26. doi: 10.1002/mds.27800.
    PubMed     Text format     Abstract available


  39. AGALLIU I, Ortega RA, Luciano MS, Mirelman A, et al
    Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Mov Disord. 2019 Jul 26. doi: 10.1002/mds.27807.
    PubMed     Text format     Abstract available


  40. BOI L, Pisanu A, Greig N, Scerba MT, et al
    Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Mov Disord. 2019 Jul 23. doi: 10.1002/mds.27799.
    PubMed     Text format     Abstract available


  41. TSUKITA K, Sakamaki-Tsukita H, Tanaka K, Suenaga T, et al
    Value of in vivo alpha-synuclein deposits in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2019 Jul 19. doi: 10.1002/mds.27794.
    PubMed     Text format     Abstract available


  42. PARK YW, Shin NY, Chung SJ, Kim J, et al
    Magnetic Resonance Imaging-Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2019 Jul 19. doi: 10.1002/mds.27798.
    PubMed     Text format     Abstract available


  43. MARAKI MI, Stefanis L, Yannakoulia M, Kosmidis MH, et al
    Motor function and the probability of prodromal Parkinson's disease in older adults.
    Mov Disord. 2019 Jul 17. doi: 10.1002/mds.27792.
    PubMed     Text format     Abstract available


  44. PRANGE S, Metereau E, Maillet A, Lhommee E, et al
    Early limbic microstructural alterations in apathy and depression in de novo Parkinson's disease.
    Mov Disord. 2019 Jul 15. doi: 10.1002/mds.27793.
    PubMed     Text format     Abstract available


  45. MOREAU C, Pinto S
    Misconceptions about speech impairment in Parkinson's disease.
    Mov Disord. 2019 Jul 15. doi: 10.1002/mds.27791.
    PubMed     Text format    


  46. MOOSA S, Martinez-Fernandez R, Elias WJ, Del Alamo M, et al
    The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27779.
    PubMed     Text format     Abstract available


  47. EVERS LJW, Krijthe JH, Meinders MJ, Bloem BR, et al
    Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27790.
    PubMed     Text format     Abstract available


  48. OERTEL WH, Henrich MT, Janzen A, Geibl FF, et al
    The locus coeruleus: Another vulnerability target in Parkinson's disease.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27785.
    PubMed     Text format    


  49. KELLY MJ, Lawton MA, Baig F, Ruffmann C, et al
    Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
    Mov Disord. 2019 Jul 8. doi: 10.1002/mds.27783.
    PubMed     Text format     Abstract available


  50. CARROLL CB, Wyse RKH, Grosset DG
    Statins and Parkinson's: A complex interaction.
    Mov Disord. 2019;34:934-935.
    PubMed     Text format    


  51. MORALES-BRICENO H, Fung VSC
    You shall not pass! Gut bacteria can convert levodopa to dopamine.
    Mov Disord. 2019;34:986.
    PubMed     Text format    


    June 2019
  52. MULLIN S, Beavan M, Bestwick J, McNeill A, et al
    Evolution and clustering of prodromal parkinsonian features in GBA1 carriers.
    Mov Disord. 2019 Jun 28. doi: 10.1002/mds.27775.
    PubMed     Text format     Abstract available


  53. VILA M
    Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease.
    Mov Disord. 2019 Jun 28. doi: 10.1002/mds.27776.
    PubMed     Text format     Abstract available


  54. COLLIER TJ, Sortwell CE, Mercado NM, Steece-Collier K, et al
    Cell therapy for Parkinson's disease: Why it doesn't work every time.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27742.
    PubMed     Text format     Abstract available


  55. NG ASL, Tan YJ, Zhao Y, Saffari SE, et al
    SNCA Rep1 promoter variability influences cognition in Parkinson's disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27768.
    PubMed     Text format     Abstract available


  56. FERNANDEZ-SANTIAGO R, Martin-Flores N, Antonelli F, Cerquera C, et al
    SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27770.
    PubMed     Text format     Abstract available


  57. HONKANEN EA, Saari L, Orte K, Gardberg M, et al
    No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27777.
    PubMed     Text format     Abstract available


  58. WICHMANN T
    Changing views of the pathophysiology of Parkinsonism.
    Mov Disord. 2019 Jun 19. doi: 10.1002/mds.27741.
    PubMed     Text format     Abstract available


  59. MATARAZZO M, Arroyo-Gallego T, Montero P, Puertas-Martin V, et al
    Remote Monitoring of Treatment Response in Parkinson's Disease: The Habit of Typing on a Computer.
    Mov Disord. 2019 Jun 18. doi: 10.1002/mds.27772.
    PubMed     Text format     Abstract available


  60. BERGSLAND N, Zivadinov R, Schweser F, Hagemeier J, et al
    Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27730.
    PubMed     Text format     Abstract available


  61. RAJPUT AH, Rajput EF, Bocking SM, Auer RN, et al
    Parkinsonism in essential tremor cases: A clinicopathological study.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27729.
    PubMed     Text format     Abstract available


  62. DE MICCO R, Esposito F, di Nardo F, Caiazzo G, et al
    Sex-related pattern of intrinsic brain connectivity in drug-naive Parkinson's disease patients.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27725.
    PubMed     Text format     Abstract available


  63. PAGANO G, Niccolini F, Wilson H, Yousaf T, et al
    Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
    Mov Disord. 2019 Jun 3. doi: 10.1002/mds.27733.
    PubMed     Text format     Abstract available


  64. JABARKHEEL Z, Wagle Shukla A
    Essential requisites for rest tremor assessment in Parkinson's disease.
    Mov Disord. 2019;34:927-929.
    PubMed     Text format    


  65. TEIVE HAG, Camargo CHF, Munhoz RP
    Reply to: Early distinction of Parkinson variant multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019;34:929.
    PubMed     Text format    


  66. OBESO JA
    Editor's note: The origin of Parkinson's disease: The importance of environment and lifestyle.
    Mov Disord. 2019;34:799-800.
    PubMed     Text format    


  67. FERNAGUT PO
    Dopamine and eating behavior disorders in Parkinson's disease: A complex recipe.
    Mov Disord. 2019;34:767-768.
    PubMed     Text format    


    May 2019
  68. HEISS JD, Lungu C, Hammoud DA, Herscovitch P, et al
    Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
    Mov Disord. 2019 May 30. doi: 10.1002/mds.27724.
    PubMed     Text format     Abstract available


  69. PARNETTI L, Bellomo G
    The issue of waste disposal in Parkinson's disease pathogenesis.
    Mov Disord. 2019 May 30. doi: 10.1002/mds.27734.
    PubMed     Text format    


  70. EVANS AH, Okai D, Weintraub D, Lim SY, et al
    Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27689.
    PubMed     Text format     Abstract available


  71. MILANESE C, Payan-Gomez C, Galvani M, Molano Gonzalez N, et al
    Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27723.
    PubMed     Text format     Abstract available


  72. LEWITT PA, Lipsman N, Kordower JH
    Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27722.
    PubMed     Text format     Abstract available


  73. SMYTH N, Skender E, David FJ, Munoz MJ, et al
    Endurance exercise reduces cortisol in Parkinson's disease with mild cognitive impairment.
    Mov Disord. 2019 May 20. doi: 10.1002/mds.27719.
    PubMed     Text format    


  74. MARRAS C, Canning CG, Goldman SM
    Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade.
    Mov Disord. 2019 May 15. doi: 10.1002/mds.27720.
    PubMed     Text format     Abstract available


  75. UCHIDA Y, Kan H, Sakurai K, Arai N, et al
    Voxel-based quantitative susceptibility mapping in Parkinson's disease with mild cognitive impairment.
    Mov Disord. 2019 May 15. doi: 10.1002/mds.27717.
    PubMed     Text format     Abstract available


  76. LI Q, Fernagut PO, Bezard E
    l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.
    Mov Disord. 2019 May 13. doi: 10.1002/mds.27715.
    PubMed     Text format    


  77. THOMASSON N, Pioli E, Friedel C, Monseur A, et al
    Engrailed-1 induces long-lasting behavior benefit in an experimental Parkinson primate model.
    Mov Disord. 2019 May 11. doi: 10.1002/mds.27714.
    PubMed     Text format    


  78. OBESO JA
    Editor's note: Prodromal Parkinson's disease.
    Mov Disord. 2019;34:664.
    PubMed     Text format    


  79. LI J, Dauer W
    Cholinergic interneurons drive maladaptive changes in thalamostriatal circuitry after dopamine depletion.
    Mov Disord. 2019;34:682.
    PubMed     Text format    


    April 2019
  80. NAM GE, Kim NH, Han K, Choi KM, et al
    Chronic renal dysfunction, proteinuria, and risk of Parkinson's disease in the elderly.
    Mov Disord. 2019 Apr 25. doi: 10.1002/mds.27704.
    PubMed     Text format     Abstract available


  81. MINEO D, Cacace F, Mancini M, Vannelli A, et al
    Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.
    Mov Disord. 2019 Apr 19. doi: 10.1002/mds.27683.
    PubMed     Text format     Abstract available


  82. CHAUDHURI KR, Jenner P, Antonini A
    Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Mov Disord. 2019 Apr 14. doi: 10.1002/mds.27691.
    PubMed     Text format    


  83. VAN DER ZEE S, Vallez Garcia D, Elsinga PH, Willemsen ATM, et al
    [(18) F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer.
    Mov Disord. 2019 Apr 12. doi: 10.1002/mds.27698.
    PubMed     Text format    


  84. CHEN Y, Cen Z, Zheng X, Pan Q, et al
    LRP10 in autosomal-dominant Parkinson's disease.
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27693.
    PubMed     Text format     Abstract available


  85. PETERSEN MS, Lophaven SN, Lynge E, Weihe P, et al
    What does migration between the faroe islands and denmark tell us about the etiology of Parkinson's disease?
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27692.
    PubMed     Text format    


  86. GRAFF S, Petkovic S
    Parkinson's disease: How do highly toxic alpha-Synuclein/PAR aggregates mediate neuronal cell death?
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27688.
    PubMed     Text format    


  87. BARBAGALLO G, Quattrone A
    Does levodopa have a disease-modifying effect in Parkinson's disease? Evidence from a delayed-start trial.
    Mov Disord. 2019 Apr 8. doi: 10.1002/mds.27686.
    PubMed     Text format    


  88. BLAUWENDRAAT C, Heilbron K, Vallerga CL, Bandres-Ciga S, et al
    Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and alpha-synuclein mechanisms.
    Mov Disord. 2019 Apr 7. doi: 10.1002/mds.27659.
    PubMed     Text format     Abstract available


  89. JEONG SM, Jang W, Shin DW
    Association of statin use with Parkinson's disease: Dose-response relationship.
    Mov Disord. 2019 Apr 2. doi: 10.1002/mds.27681.
    PubMed     Text format     Abstract available


  90. LI Y, Wang C, Wang J, Zhou Y, et al
    Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus.
    Mov Disord. 2019 Apr 2. doi: 10.1002/mds.27682.
    PubMed     Text format     Abstract available



  91. 32nd ANNUAL SYMPOSIUM ON ETIOLOGY, PATHOGENESIS, AND TREATMENT OF PARKINSON DISEASE AND OTHER MOVEMENT DISORDERS.
    Mov Disord. 2019;34.
    PubMed     Text format    


    March 2019
  92. LANG S, Hanganu A, Gan LS, Kibreab M, et al
    Network basis of the dysexecutive and posterior cortical cognitive profiles in Parkinson's disease.
    Mov Disord. 2019 Mar 29. doi: 10.1002/mds.27674.
    PubMed     Text format     Abstract available


  93. POSTUMA RB, Berg D
    Prodromal Parkinson's Disease: The Decade Past, the Decade to Come.
    Mov Disord. 2019 Mar 28. doi: 10.1002/mds.27670.
    PubMed     Text format     Abstract available


  94. WEINTRAUB D
    Impulse control disorders in Parkinson's disease: A 20-year odyssey.
    Mov Disord. 2019 Mar 26. doi: 10.1002/mds.27668.
    PubMed     Text format    


  95. PRICE RJ, Fisher DG, Suk JS, Hanes J, et al
    Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier?
    Mov Disord. 2019 Mar 25. doi: 10.1002/mds.27675.
    PubMed     Text format    


  96. ESPAY AJ, Hausdorff JM, Sanchez-Ferro A, Klucken J, et al
    A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies.
    Mov Disord. 2019 Mar 22. doi: 10.1002/mds.27671.
    PubMed     Text format     Abstract available


  97. VIZCARRA JA, Sanchez-Ferro A, Maetzler W, Marsili L, et al
    The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.
    Mov Disord. 2019 Mar 22. doi: 10.1002/mds.27673.
    PubMed     Text format    


  98. ARLOTTI M, Palmisano C, Minafra B, Todisco M, et al
    Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient.
    Mov Disord. 2019 Mar 20. doi: 10.1002/mds.27657.
    PubMed     Text format    


  99. MORRIS R, Yarnall AJ, Hunter H, Taylor JP, et al
    Noninvasive vagus nerve stimulation to target gait impairment in Parkinson's disease.
    Mov Disord. 2019 Mar 19. doi: 10.1002/mds.27664.
    PubMed     Text format    


  100. GUO Y, Xu W, Liu FT, Li JQ, et al
    Modifiable risk factors for cognitive impairment in Parkinson's disease: A systematic review and meta-analysis of prospective cohort studies.
    Mov Disord. 2019 Mar 14. doi: 10.1002/mds.27665.
    PubMed     Text format     Abstract available


  101. MONDAL B, Choudhury S, Simon B, Baker MR, et al
    Noninvasive vagus nerve stimulation improves gait and reduces freezing of gait in Parkinson's disease.
    Mov Disord. 2019 Mar 14. doi: 10.1002/mds.27662.
    PubMed     Text format    


  102. DE HEMPTINNE C, Wang DD, Miocinovic S, Chen W, et al
    Pallidal thermolesion unleashes gamma oscillations in the motor cortex in Parkinson's disease.
    Mov Disord. 2019 Mar 13. doi: 10.1002/mds.27658.
    PubMed     Text format     Abstract available


  103. KANG UJ, Boehme AK, Fairfoul G, Shahnawaz M, et al
    Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.
    Mov Disord. 2019 Mar 6. doi: 10.1002/mds.27646.
    PubMed     Text format     Abstract available


  104. MAGHZI H, Hogg EJ, Tan E, Pagano G, et al
    Adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Mov Disord. 2019;34:442.
    PubMed     Text format    


    February 2019
  105. FARRER MJ, Follett J
    Endosomal trafficking leads the way in Parkinson's disease.
    Mov Disord. 2019 Feb 27. doi: 10.1002/mds.27647.
    PubMed     Text format    


  106. ALCALAY RN, Mallett V, Vanderperre B, Tavassoly O, et al
    SMPD1 mutations, activity, and alpha-synuclein accumulation in Parkinson's disease.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27642.
    PubMed     Text format     Abstract available


  107. LIN CH, Chen PL, Tai CH, Lin HI, et al
    A clinical and genetic study of early-onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and next-generation sequencing.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27633.
    PubMed     Text format     Abstract available


  108. FANCIULLI A, Goebel G, Lazzeri G, Scherfler C, et al
    Early distinction of Parkinson-variant multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27635.
    PubMed     Text format    


  109. IKEDA A, Shimada H, Nishioka K, Takanashi M, et al
    Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features.
    Mov Disord. 2019 Feb 17. doi: 10.1002/mds.27623.
    PubMed     Text format     Abstract available


  110. QUATTRONE A, Morelli M, Vescio B, Nigro S, et al
    Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.
    Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27621.
    PubMed     Text format     Abstract available


  111. DIEDERICH NJ, James Surmeier D, Uchihara T, Grillner S, et al
    Parkinson's disease: Is it a consequence of human brain evolution?
    Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27628.
    PubMed     Text format    


  112. SCHRAG A, Anastasiou Z, Ambler G, Noyce A, et al
    Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentations.
    Mov Disord. 2019 Feb 8. doi: 10.1002/mds.27616.
    PubMed     Text format     Abstract available


  113. YSSELSTEIN D, Shulman JM, Krainc D
    Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.
    Mov Disord. 2019 Feb 6. doi: 10.1002/mds.27631.
    PubMed     Text format     Abstract available


  114. DAFSARI HS, Martinez-Martin P, Rizos A, Trost M, et al
    EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
    Mov Disord. 2019 Feb 4. doi: 10.1002/mds.27626.
    PubMed     Text format     Abstract available


  115. HENDERSHOTT TR, Zhu D, Llanes S, Zabetian CP, et al
    Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
    Mov Disord. 2019;34:285-291.
    PubMed     Text format     Abstract available


    January 2019
  116. HUANG X, Sterling NW, Du G, Sun D, et al
    Brain cholesterol metabolism and Parkinson's disease.
    Mov Disord. 2019 Jan 25. doi: 10.1002/mds.27609.
    PubMed     Text format     Abstract available


  117. ATKINSON-CLEMENT C, Cavazzini E, Zenon A, Witjas T, et al
    Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.
    Mov Disord. 2019 Jan 25. doi: 10.1002/mds.27625.
    PubMed     Text format     Abstract available


  118. BLESA J, Vila M
    Parkinson disease, substantia nigra vulnerability, and calbindin expression: Enlightening the darkness?
    Mov Disord. 2019 Jan 24. doi: 10.1002/mds.27618.
    PubMed     Text format    


  119. BANDRES-CIGA S, Saez-Atienzar S, Bonet-Ponce L, Billingsley K, et al
    The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease.
    Mov Disord. 2019 Jan 24. doi: 10.1002/mds.27614.
    PubMed     Text format     Abstract available


  120. HOOGLAND J, Boel JA, de Bie RMA, Schmand BA, et al
    Risk of Parkinson's disease dementia related to level I MDS PD-MCI.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27617.
    PubMed     Text format     Abstract available


  121. SEPPI K, Ray Chaudhuri K, Coelho M, Fox SH, et al
    Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27602.
    PubMed     Text format     Abstract available


  122. WARREN OLANOW C, Torti M, Kieburtz K, Leinonen M, et al
    Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27610.
    PubMed     Text format     Abstract available


  123. MARRAS C, Obeso JA
    We are what we eat - editors' note on the role of diet in Parkinson's disease.
    Mov Disord. 2019;34:1.
    PubMed     Text format    


  124. PAUL KC, Chuang YH, Shih IF, Keener A, et al
    The association between lifestyle factors and Parkinson's disease progression and mortality.
    Mov Disord. 2019;34:58-66.
    PubMed     Text format     Abstract available


  125. ASCHERIO A, Schwarzschild MA
    Lifestyle and Parkinson's disease progression.
    Mov Disord. 2019;34:7-8.
    PubMed     Text format    


  126. GRONICH N, Auriel E, Lavi I, Rennert G, et al
    Reply to: From beta-blockers to Parkinson's disease in respect of essential tremor.
    Mov Disord. 2019;34:154.
    PubMed     Text format    



  127. Retraction: 'Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients,' by Sato Y., Honda Y., Iwamoto, J., Kanoko, T., and Satoh, K.
    Mov Disord. 2019;34:156.
    PubMed     Text format    


  128. VOGELNIK K, Kojovic M
    From beta-blockers to Parkinson's disease in respect of essential tremor.
    Mov Disord. 2019;34:153.
    PubMed     Text format    


  129. RICCIARDI L, Sorbera C, Barbuto M, Morgante F, et al
    Sleep disturbances are mainly improved by deep brain stimulation of the subthalamic nucleus.
    Mov Disord. 2019;34:154-155.
    PubMed     Text format    


    December 2018
  130. LANGLEY J, He N, Huddleston DE, Chen S, et al
    Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27608.
    PubMed     Text format     Abstract available


  131. BONANNI L
    The democratic aspect of machine learning: Limitations and opportunities for Parkinson's disease.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27600.
    PubMed     Text format    


  132. KIM JJ, Bandres-Ciga S
    The appendix and the risk of Parkinson's disease: Appended notes on correlation and causation.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27599.
    PubMed     Text format    


  133. ATASHRAZM F, Hammond D, Perera G, Bolliger MF, et al
    LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27601.
    PubMed     Text format     Abstract available


  134. MORGANTE F, Valente EM
    LRP10: A novel disease gene bridging Parkinson's disease and dementia with Lewy body.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27593.
    PubMed     Text format    


  135. MARTINEZ-MARTIN P, Macaulay D, Jalundhwala YJ, Mu F, et al
    The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States.
    Mov Disord. 2018 Dec 27. doi: 10.1002/mds.27579.
    PubMed     Text format     Abstract available


  136. BARICHELLA M, Severgnini M, Cilia R, Cassani E, et al
    Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism.
    Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27581.
    PubMed     Text format     Abstract available


  137. JOHNSTON TH, Geva M, Steiner L, Orbach A, et al
    Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27565.
    PubMed     Text format     Abstract available


  138. STARHOF C, Hejl AM, Heegaard NHH, Carlsen AL, et al
    The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.
    Mov Disord. 2018 Dec 17. doi: 10.1002/mds.27542.
    PubMed     Text format     Abstract available


  139. CHUNG SJ, Jeon S, Yoo HS, Yoon JH, et al
    Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27580.
    PubMed     Text format    


  140. TRINH J, Lohmann K, Baumann H, Balck A, et al
    Utility and implications of exome sequencing in early-onset Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27559.
    PubMed     Text format     Abstract available


  141. BEJR-KASEM H, Pagonabarraga J, Martinez-Horta S, Sampedro F, et al
    Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27557.
    PubMed     Text format     Abstract available


  142. ASSAF F, Schiller Y
    A chemogenetic approach for treating experimental Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27554.
    PubMed     Text format     Abstract available


  143. GARGOURI F, Gallea C, Mongin M, Pyatigorskaya N, et al
    Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27561.
    PubMed     Text format     Abstract available


    November 2018
  144. CUI SS, Du JJ, Liu SH, Meng J, et al
    Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27569.
    PubMed     Text format     Abstract available


  145. IRMEN F, Horn A, Meder D, Neumann WJ, et al
    Sensorimotor subthalamic stimulation restores risk-reward trade-off in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27576.
    PubMed     Text format     Abstract available


  146. JANKOVIC J
    Pathogenesis-targeted therapeutic strategies in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27534.
    PubMed     Text format    


  147. KRISTIANSEN M, Maple-Grodem J, Alves G, Arepalli S, et al
    A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27555.
    PubMed     Text format    


  148. MOLLENHAUER B, Zimmermann J, Sixel-Doring F, Focke NK, et al
    Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mov Disord. 2018 Nov 23. doi: 10.1002/mds.27492.
    PubMed     Text format     Abstract available


  149. SANJARI MOGHADDAM H, Aarabi MH
    Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Mov Disord. 2018 Nov 19. doi: 10.1002/mds.27509.
    PubMed     Text format    


  150. DARVISH H, Bravo P, Tafakhori A, Azcona LJ, et al
    Identification of a large homozygous VPS13C deletion in a patient with early-onset Parkinsonism.
    Mov Disord. 2018 Nov 19. doi: 10.1002/mds.27516.
    PubMed     Text format    


  151. CORMIER-DEQUAIRE F, Bekadar S, Anheim M, Lebbah S, et al
    Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.
    Mov Disord. 2018 Nov 16. doi: 10.1002/mds.27519.
    PubMed     Text format     Abstract available


  152. LOFREDI R, Neumann WJ, Brucke C, Huebl J, et al
    Pallidal beta bursts in Parkinson's disease and dystonia.
    Mov Disord. 2018 Nov 15. doi: 10.1002/mds.27524.
    PubMed     Text format     Abstract available


  153. LYNCH WB, Tschumi CW, Sharpe AL, Branch SY, et al
    Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson's Model.
    Mov Disord. 2018 Nov 15. doi: 10.1002/mds.27541.
    PubMed     Text format     Abstract available


  154. MOHAMED IBRAHIM N, Ramli R, Koya Kutty S, Shah SA, et al
    Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus.
    Mov Disord. 2018 Nov 14. doi: 10.1002/mds.27526.
    PubMed     Text format    


  155. PICILLO M, Lizarraga KJ, Friesen EL, Chau H, et al
    Parkinsonism due to A53E alpha-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27506.
    PubMed     Text format     Abstract available


  156. FRIEDERICH A, Flinspach A, Suenkel U, Eschweiler GW, et al
    Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27539.
    PubMed     Text format    


  157. DELGADO-ALVARADO M, Dacosta-Aguayo R, Navalpotro-Gomez I, Gago B, et al
    Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27518.
    PubMed     Text format     Abstract available


  158. PUTZOLU M, Pelosin E, Ogliastro C, Lagravinese G, et al
    Anodal tDCS over prefrontal cortex improves dual-task walking in Parkinsonian patients with freezing.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27533.
    PubMed     Text format    


  159. KUIPERS DJS, Carr J, Bardien S, Thomas P, et al
    PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability.
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27501.
    PubMed     Text format     Abstract available


  160. POSTUMA RB
    Mediterranean diets and prodromal Parkinson's disease: A causal line, or a confound circle?
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27538.
    PubMed     Text format    


  161. ALBIN RL, Surmeier DJ, Tubert C, Sarter M, et al
    Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27540.
    PubMed     Text format    


  162. TANGNEY CC
    Diet to beat the odds of prodromal Parkinson's disease?
    Mov Disord. 2018 Nov 5. doi: 10.1002/mds.27520.
    PubMed     Text format    


  163. ESPAY AJ, Guskey MT, Norton JC, Coate B, et al
    Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
    Mov Disord. 2018 Nov 2. doi: 10.1002/mds.27488.
    PubMed     Text format     Abstract available


  164. OLANOW CW, Kenney C, Bandak S, Kieburtz KD, et al
    Adverse event reporting in clinical trials in Parkinson's Disease: Time for change.
    Mov Disord. 2018 Nov 1. doi: 10.1002/mds.27497.
    PubMed     Text format    


  165. SAMOTUS O, Jog M
    Reply to: Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1829-1830.
    PubMed     Text format    


  166. MEADOWS SM, Conti MM, Gross L, Chambers NE, et al
    Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Mov Disord. 2018;33:1740-1749.
    PubMed     Text format     Abstract available


  167. DE SOUZA CP, Dos Santos MGG, Hamani C, Fonoff ET, et al
    Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1828-1829.
    PubMed     Text format    


    October 2018
  168. SACHELI MA, Murray DK, Vafai N, Cherkasova MV, et al
    Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study.
    Mov Disord. 2018 Oct 30. doi: 10.1002/mds.27498.
    PubMed     Text format     Abstract available


  169. TRINH J, Zeldenrust FMJ, Huang J, Kasten M, et al
    Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
    Mov Disord. 2018 Oct 24. doi: 10.1002/mds.27527.
    PubMed     Text format     Abstract available


  170. HABETS JGV, Heijmans M, Kuijf ML, Janssen MLF, et al
    An update on adaptive deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Oct 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  171. BETROUNI N, Delval A, Chaton L, Defebvre L, et al
    Electroencephalography-based machine learning for cognitive profiling in Parkinson's disease: Preliminary results.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27528.
    PubMed     Text format     Abstract available


  172. HUANG X, Ng SY, Chia NS, Acharyya S, et al
    Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27521.
    PubMed     Text format    


  173. WEERSINK JB, Eikelboom C, Dominguez Vega ZT, Maurits NM, et al
    Forward arm extension as a cue for gait initiation in Parkinson's patients.
    Mov Disord. 2018 Oct 17. doi: 10.1002/mds.27510.
    PubMed     Text format    


  174. TOSSERAMS A, Araujo R, Pringsheim T, Post B, et al
    Underrepresentation of women in Parkinson's disease trials.
    Mov Disord. 2018 Oct 11. doi: 10.1002/mds.27505.
    PubMed     Text format    


  175. MARAKI MI, Yannakoulia M, Stamelou M, Stefanis L, et al
    Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27489.
    PubMed     Text format     Abstract available


  176. VIRMANI T, Pillai L, Glover A, Doerhoff SM, et al
    Impaired step-length setting prior to turning in Parkinson's disease patients with freezing of gait.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27499.
    PubMed     Text format    


  177. FABER I, Martinez ARM, Martins CR Jr, Maia ML, et al
    SPG11-related parkinsonism: Clinical profile, molecular imaging and l-dopa response.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27491.
    PubMed     Text format     Abstract available


  178. HOLDEN SK, Medina LD, Hoyt B, Sillau SH, et al
    Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27487.
    PubMed     Text format     Abstract available


  179. BLAUWENDRAAT C, Bras JM, Nalls MA, Lewis PA, et al
    Coding variation in GBA explains the majority of the SYT11-GBA Parkinson's disease GWAS locus.
    Mov Disord. 2018 Oct 9. doi: 10.1002.
    PubMed     Text format    


  180. WALDTHALER J, Tsitsi P, Seimyr GO, Benfatto MN, et al
    Eye movements during reading in parkinson's disease: A pilot study.
    Mov Disord. 2018 Oct 8. doi: 10.1002.
    PubMed     Text format    


  181. SMITH AM, Depp C, Ryan BJ, Johnston GI, et al
    Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells.
    Mov Disord. 2018 Oct 7. doi: 10.1002.
    PubMed     Text format     Abstract available


  182. THALER A, Kozlovski T, Gurevich T, Bar-Shira A, et al
    Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27490.
    PubMed     Text format     Abstract available


  183. GREENAMYRE JT
    What's wrong with mitochondria in Parkinson's disease?
    Mov Disord. 2018 Oct 4. doi: 10.1002.
    PubMed     Text format    


  184. VAN DER VELDEN RMJ, Mulders AEP, Drukker M, Kuijf ML, et al
    Network analysis of symptoms in a Parkinson patient using experience sampling data: An n = 1 study.
    Mov Disord. 2018 Oct 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  185. KOROS C, Simitsi A, Prentakis A, Beratis I, et al
    123I-FP-CIT SPECT [(123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T alpha-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27451.
    PubMed     Text format     Abstract available


  186. BEACH TG, Adler CH
    Importance of low diagnostic Accuracy for early Parkinson's disease.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27485.
    PubMed     Text format    


  187. BURCIU RG, Vaillancourt DE
    Imaging of Motor Cortex Physiology in Parkinson's Disease.
    Mov Disord. 2018 Oct 2. doi: 10.1002.
    PubMed     Text format     Abstract available



  188. Abstracts of the 2018 International Congress of Parkinson's Disease and Movement Disorders((R)).
    Mov Disord. 2018;33 Suppl 2:S1-S929.
    PubMed     Text format    


  189. DULOVIC M, Vos M
    Sleep dysfunction in Parkinson's disease: Novel molecular mechanism and implications for therapy.
    Mov Disord. 2018;33:1558-1559.
    PubMed     Text format    


  190. SCHRAG A
    Testing the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018;33:1518-1520.
    PubMed     Text format    


  191. WAGLE SHUKLA A, Fox SH
    Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.
    Mov Disord. 2018;33:1560.
    PubMed     Text format    


    September 2018
  192. BARTHEL C, van Helvert M, Haan R, Janssen AM, et al
    Visual cueing using laser shoes reduces freezing of gait in parkinson's patients at home.
    Mov Disord. 2018 Sep 29. doi: 10.1002/mds.27455.
    PubMed     Text format    


  193. RAMIG L, Halpern A, Spielman J, Fox C, et al
    Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27460.
    PubMed     Text format     Abstract available


  194. SICILIANO M, Trojano L, Santangelo G, De Micco R, et al
    Fatigue in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27461.
    PubMed     Text format     Abstract available


  195. FABBRI M, Ferreira JJ, Lees A, Stocchi F, et al
    Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Mov Disord. 2018 Sep 27. doi: 10.1002/mds.27475.
    PubMed     Text format     Abstract available


  196. VAN DER VELDEN RMJ, Broen MPG, Kuijf ML, Leentjens AFG, et al
    Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review.
    Mov Disord. 2018 Sep 17. doi: 10.1002/mds.27465.
    PubMed     Text format     Abstract available


  197. LOHLE M, Mangone G, Wolz M, Beuthien-Baumann B, et al
    Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
    Mov Disord. 2018 Sep 14. doi: 10.1002/mds.27466.
    PubMed     Text format     Abstract available


  198. LUBOMSKI M, Hayes M, Kennerson M, Ellis M, et al
    A novel Parkinson's disease risk variant, p. W378R, in the Gaucher's disease GBA gene.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format    


  199. HOOGLAND J, van Wanrooij LL, Boel JA, Goldman JG, et al
    Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  200. MESTRE TA
    Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format    


  201. CHARVIN D, Di Paolo T, Bezard E, Gregoire L, et al
    An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Mov Disord. 2018 Sep 14. doi: 10.1002/mds.27462.
    PubMed     Text format     Abstract available


  202. PALACIOS N, Hughes KC, Cereda E, Schwarzschild MA, et al
    Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  203. YORITAKA A, Ohtsuka C, Maeda T, Hirayama M, et al
    Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease.
    Mov Disord. 2018 Sep 12. doi: 10.1002/mds.27472.
    PubMed     Text format    


  204. NEVES MA, Bouca-Machado R, Guerreiro D, Canica V, et al
    Risk of drowning in people with Parkinson's disease.
    Mov Disord. 2018 Sep 12. doi: 10.1002/mds.27473.
    PubMed     Text format    


  205. PCHELINA S, Baydakova G, Nikolaev M, Senkevich K, et al
    Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations.
    Mov Disord. 2018 Sep 7. doi: 10.1002/mds.27393.
    PubMed     Text format     Abstract available


  206. GAARE JJ, Nido GS, Sztromwasser P, Knappskog PM, et al
    Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease.
    Mov Disord. 2018 Sep 5. doi: 10.1002.
    PubMed     Text format     Abstract available


  207. GUO L, Normando EM, Shah PA, De Groef L, et al
    Oculo-visual abnormalities in Parkinson's disease: Possible value as biomarkers.
    Mov Disord. 2018;33:1390-1406.
    PubMed     Text format     Abstract available


  208. VAILLANCOURT DE, Lehericy S
    Illuminating basal ganglia and beyond in Parkinson's disease.
    Mov Disord. 2018;33:1373-1375.
    PubMed     Text format    


  209. GRONICH N, Abernethy DR, Auriel E, Lavi I, et al
    beta2-adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Mov Disord. 2018;33:1465-1471.
    PubMed     Text format     Abstract available


    August 2018
  210. INOUE KI, Miyachi S, Nishi K, Okado H, et al
    Recruitment of calbindin into nigral dopamine neurons protects against MPTP-Induced parkinsonism.
    Mov Disord. 2018 Aug 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  211. BERG D, Adler CH, Bloem BR, Chan P, et al
    Movement disorder society criteria for clinically established early Parkinson's disease.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27431.
    PubMed     Text format     Abstract available


  212. ROZANI V, Gurevich T, Giladi N, El-Ad B, et al
    Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27413.
    PubMed     Text format     Abstract available


  213. MESTRE TA, Shamy M, Benedetti F, Lang AE, et al
    Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27409.
    PubMed     Text format     Abstract available


  214. SIEURIN J, Andel R, Tillander A, Valdes EG, et al
    Occupational stress and risk for Parkinson's disease: A nationwide cohort study.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27439.
    PubMed     Text format     Abstract available


  215. DEFFAINS M, Iskhakova L, Katabi S, Israel Z, et al
    Longer beta oscillatory episodes reliably identify pathological subthalamic activity in Parkinsonism.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27418.
    PubMed     Text format     Abstract available


  216. WANNEVEICH M, Moisan F, Jacqmin-Gadda H, Elbaz A, et al
    Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010-2030) in France.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27447.
    PubMed     Text format     Abstract available


  217. POSTUMA RB, Poewe W, Litvan I, Lewis S, et al
    Validation of the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27362.
    PubMed     Text format     Abstract available


  218. LERCHE S, Liepelt-Scarfone I, Wurster I, Schulte C, et al
    Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease.
    Mov Disord. 2018 Aug 22. doi: 10.1002/mds.27427.
    PubMed     Text format     Abstract available


  219. WITEK N, Stebbins GT, Goetz CG
    What influences placebo and nocebo responses in Parkinson's disease?
    Mov Disord. 2018 Aug 22. doi: 10.1002/mds.27416.
    PubMed     Text format     Abstract available


  220. PHILLIPS MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, et al
    Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial.
    Mov Disord. 2018 Aug 11. doi: 10.1002/mds.27390.
    PubMed     Text format     Abstract available


  221. MESTRE TA, Ferreira JJ
    The placebo response in Parkinson's disease and other movement disorders.
    Mov Disord. 2018;33:1193-1194.
    PubMed     Text format    


  222. SKORVANEK M, Gelpi E, Mechirova E, Ladomirjakova Z, et al
    alpha-Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa.
    Mov Disord. 2018;33:1366-1368.
    PubMed     Text format    


  223. FERREIRA JJ, Trenkwalder C, Mestre TA
    Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?
    Mov Disord. 2018;33:1228-1235.
    PubMed     Text format     Abstract available


  224. QUATTRONE A, Barbagallo G, Cerasa A, Stoessl AJ, et al
    Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
    Mov Disord. 2018;33:1213-1227.
    PubMed     Text format     Abstract available


    July 2018
  225. PITCHER TL, Myall DJ, Pearson JF, Lacey CJ, et al
    Parkinson's disease across ethnicities: A nationwide study in New Zealand.
    Mov Disord. 2018 Jul 23. doi: 10.1002/mds.27389.
    PubMed     Text format     Abstract available


  226. GUPTA DK, Fahn S, Tatsuoka C, Kang UJ, et al
    Hoehn and Yahr stage 3 and postural stability item in the movement disorder society-unified Parkinson's disease rating scale.
    Mov Disord. 2018;33:1188-1189.
    PubMed     Text format    


  227. LOESCH DZ, Tassone F, Mellick GD, Horne M, et al
    Evidence for the role of FMR1 gray zone alleles as a risk factor for parkinsonism in females.
    Mov Disord. 2018;33:1178-1181.
    PubMed     Text format     Abstract available


  228. REYES CJ, Westenberger A
    An integrated OMICS approach unravels the elusive genetic cause of X-linked dystonia-parkinsonism.
    Mov Disord. 2018;33:1095.
    PubMed     Text format    


  229. SANTENS P, De Letter M, Lees AJ, Krack P, et al
    Crime and Parkinson's: The jury is out.
    Mov Disord. 2018;33:1092-1094.
    PubMed     Text format    


  230. SKORVANEK M, Martinez-Martin P, Stebbins GT, Goetz CG, et al
    Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Mov Disord. 2018;33:1189-1190.
    PubMed     Text format    


  231. RAKOVIC A, Domingo A, Grutz K, Kulikovskaja L, et al
    Genome editing in induced pluripotent stem cells rescues TAF1 levels in X-linked dystonia-parkinsonism.
    Mov Disord. 2018;33:1108-1118.
    PubMed     Text format     Abstract available


  232. EHGOETZ MARTENS KA, Shine JM, Walton CC, Georgiades MJ, et al
    Evidence for subtypes of freezing of gait in Parkinson's disease.
    Mov Disord. 2018;33:1174-1178.
    PubMed     Text format     Abstract available


    June 2018

  233. Abstracts of the 2nd Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2018;33.
    PubMed     Text format    


    May 2018
  234. SOMMERAUER M, Hansen AK, Parbo P, Fedorova TD, et al
    Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients.
    Mov Disord. 2018 May 24. doi: 10.1002/mds.27411.
    PubMed     Text format     Abstract available


  235. CHARLES KA, Naudet F, Bouali-Benazzouz R, Landry M, et al
    Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease.
    Mov Disord. 2018 May 18. doi: 10.1002/mds.27377.
    PubMed     Text format     Abstract available


  236. LI J, Ruskey JA, Arnulf I, Dauvilliers Y, et al
    Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27385.
    PubMed     Text format     Abstract available


  237. DU G, Lewis MM, Sica C, He L, et al
    Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27318.
    PubMed     Text format     Abstract available


  238. TANIGUCHI D, Hatano T, Kamagata K, Okuzumi A, et al
    Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27365.
    PubMed     Text format     Abstract available


  239. HELDMANN M, Heeren J, Klein C, Rauch L, et al
    Neuroimaging abnormalities in individuals exhibiting Parkinson's disease risk markers.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27313.
    PubMed     Text format     Abstract available


  240. MEROLA A, Romagnolo A, Lopiano L, Espay AJ, et al
    Reply to: "Autonomic dysfunction in Parkinson's disease: The hidden game changer?"
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27421.
    PubMed     Text format    


  241. DE PABLO-FERNANDEZ E, Warner TT
    Autonomic dysfunction in Parkinson's disease: The hidden game changer?
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27422.
    PubMed     Text format    


  242. BAUFRETON J, Milekovic T, Li Q, McGuire S, et al
    Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27404.
    PubMed     Text format     Abstract available


  243. LEWIS MM, Du G, Baccon J, Snyder AM, et al
    Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27381.
    PubMed     Text format     Abstract available


  244. ORTUNO-LIZARAN I, Beach TG, Serrano GE, Walker DG, et al
    Phosphorylated alpha-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.
    Mov Disord. 2018 May 8. doi: 10.1002/mds.27392.
    PubMed     Text format     Abstract available


  245. LEWITT PA
    Comment on 'Distinct metabolomic signature in cerebrospinal fluid in early Parkinson's disease' by Hiller et al.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27379.
    PubMed     Text format    


  246. CEDARBAUM JM
    Elephants, Parkinson's disease, and proof-of-concept clinical trials.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27398.
    PubMed     Text format    


  247. TREZZI JP, Hiller K, Mollenhauer B
    The importance of an independent validation cohort for metabolomics biomarker studies.
    Mov Disord. 2018;33:856.
    PubMed     Text format    


    April 2018
  248. LIPSMEIER F, Taylor KI, Kilchenmann T, Wolf D, et al
    Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27376.
    PubMed     Text format     Abstract available


  249. SARDI SP, Cedarbaum JM, Brundin P
    Targeted therapies for Parkinson's disease: From genetics to the clinic.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27414.
    PubMed     Text format     Abstract available


  250. HANGANU A, Houde JC, Fonov VS, Degroot C, et al
    White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease.
    Mov Disord. 2018 Apr 23. doi: 10.1002/mds.27364.
    PubMed     Text format     Abstract available


  251. LEFAIVRE SC, Brown MJN, Almeida QJ
    Does cerebellar overactivity contribute to gait and balance deficits in Parkinson's disease?
    Mov Disord. 2018 Apr 20. doi: 10.1002/mds.27396.
    PubMed     Text format    


  252. MESTRE TA, Pont-Sunyer C, Kausar F, Visanji NP, et al
    Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mov Disord. 2018 Apr 17. doi: 10.1002/mds.27272.
    PubMed     Text format     Abstract available


  253. CONTARINO MF, Marinus J, van Hilten JJ
    Does deep brain stimulation of the subthalamic nucleus prolong survival in Parkinson's Disease?
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27384.
    PubMed     Text format    


  254. FRIEDMAN JH
    Quetiapine for Parkinson's Disease psychosis: Evidence-based medicine versus expert belief: A case study.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27378.
    PubMed     Text format    


  255. LANG AE, Espay AJ
    Disease modification in Parkinson's Disease: Current approaches, challenges, and future considerations.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27360.
    PubMed     Text format     Abstract available


  256. KASTEN M, Hartmann C, Hampf J, Schaake S, et al
    Genotype-phenotype relations for the Parkinson's Disease genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27352.
    PubMed     Text format     Abstract available


  257. AMANAT M, Salehi M
    Glitazone in Parkinson's Disease.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27397.
    PubMed     Text format    


  258. SCOTT KM, Williams-Gray CH
    Targeting aged astrocytes may be a new therapeutic strategy in Parkinson's disease.
    Mov Disord. 2018 Apr 6. doi: 10.1002/mds.27387.
    PubMed     Text format    


    March 2018
  259. MACEROLLO A, Brown MJN
    Beta oscillations and indirect pathway spiny projecting neurons: A selective neuronal mechanism linked to Parkinsonian pathophysiology?
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27388.
    PubMed     Text format    


  260. WEIR S, Samnaliev M, Kuo TC, Tierney TS, et al
    Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27302.
    PubMed     Text format     Abstract available


  261. KORDOWER JH, Burke RE
    Disease modification for Parkinson's disease: Axonal regeneration and trophic factors.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27383.
    PubMed     Text format     Abstract available


  262. COSSU G, Melis M, Sarchioto M, Melis M, et al
    6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27391.
    PubMed     Text format     Abstract available


  263. LITVAN I, Kieburtz K, Troster AI, Aarsland D, et al
    Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27345.
    PubMed     Text format     Abstract available


  264. KADHIM S, Pringsheim T, Le A, Fiest KM, et al
    Validating screening tools for depression in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27371.
    PubMed     Text format    


  265. MOGHADDAM HS, Arabi MH
    Synaptotagmin-11 Is a novel hotspot in the pathogenesis of parkin-linked Parkinson's disease: New implications for clinical targeting.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27369.
    PubMed     Text format    


  266. HOUSER MC, Chang J, Factor SA, Molho ES, et al
    Stool immune profiles evince gastrointestinal inflammation in Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27326.
    PubMed     Text format     Abstract available


  267. SIMUNI T, Siderowf A, Lasch S, Coffey CS, et al
    Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27361.
    PubMed     Text format     Abstract available


  268. FOX SH, Katzenschlager R, Lim SY, Barton B, et al
    International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27372.
    PubMed     Text format     Abstract available


  269. FASANO A, De Vloo P, Llinas M, Hlasny E, et al
    Magnetic resonance imaging-guided focused ultrasound thalamotomy in Parkinson tremor: Reoperation after benefit decay.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27348.
    PubMed     Text format    


  270. ANTONINI A, Moro E, Godeiro C, Reichmann H, et al
    Medical and surgical management of advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27340.
    PubMed     Text format     Abstract available


  271. FERNANDEZ HH, Boyd JT, Fung VSC, Lew MF, et al
    Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27338.
    PubMed     Text format     Abstract available


  272. HEINZEL S, Kasten M, Behnke S, Vollstedt EJ, et al
    Age- and sex-related heterogeneity in prodromal Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27349.
    PubMed     Text format    


  273. WEINTRAUB D, Troster AI, Marras C, Stebbins G, et al
    Initial cognitive changes in Parkinson's disease.
    Mov Disord. 2018 Mar 15. doi: 10.1002/mds.27330.
    PubMed     Text format     Abstract available


  274. CARDOSO F
    Vitamin B12 and Parkinson's disease: What is the relationship?
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27366.
    PubMed     Text format    


  275. BECK G, Maehara S, Chang PL, Papa SM, et al
    A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27341.
    PubMed     Text format     Abstract available


  276. CHRISTINE CW, Auinger P, Joslin A, Yelpaala Y, et al
    Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson's disease.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27301.
    PubMed     Text format     Abstract available


  277. PALMA JA, Kaufmann H
    Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.
    Mov Disord. 2018;33:372-390.
    PubMed     Text format     Abstract available


  278. CHEN X, Scholz SW
    Identification of new alpha-synuclein regulator by nontraditional drug development pipeline.
    Mov Disord. 2018;33:402.
    PubMed     Text format    


    February 2018
  279. SONG W, Kothari V, Velly AM, Cressatti M, et al
    Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27328.
    PubMed     Text format     Abstract available


  280. GOLDMAN JG, Holden SK, Litvan I, McKeith I, et al
    Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27323.
    PubMed     Text format     Abstract available


  281. MORALES-BRICENO H, Sanchez-Hernandez BE, Meyer E, Kurian MA, et al
    Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27294.
    PubMed     Text format    


  282. CENCI MA, Crossman AR
    Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27337.
    PubMed     Text format     Abstract available


  283. MENG Y, Voisin MR, Suppiah S, Kalia SK, et al
    Is there a role for MR-guided focused ultrasound in Parkinson's disease?
    Mov Disord. 2018 Feb 24. doi: 10.1002/mds.27308.
    PubMed     Text format    


  284. WEIL RS, Schwarzkopf DS, Bahrami B, Fleming SM, et al
    Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo-perceptual deficits.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27311.
    PubMed     Text format     Abstract available


  285. PERAN P, Barbagallo G, Nemmi F, Sierra M, et al
    MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27307.
    PubMed     Text format     Abstract available


  286. ARGAUD S, Verin M, Sauleau P, Grandjean D, et al
    Facial emotion recognition in Parkinson's disease: A review and new hypotheses.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27305.
    PubMed     Text format     Abstract available


  287. FERNANDEZ-SANTIAGO R, Garrido A, Infante J, Gonzalez-Aramburu I, et al
    alpha-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27295.
    PubMed     Text format     Abstract available


  288. DAFSARI HS, Silverdale M, Strack M, Rizos A, et al
    Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2018 Feb 21. doi: 10.1002/mds.27283.
    PubMed     Text format     Abstract available


  289. FEDERICO A, Tinazzi M, Tamburin S
    MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27329.
    PubMed     Text format    


  290. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27339.
    PubMed     Text format    


  291. WYMAN-CHICK KA, Martin PK, Weintraub D, Sperling SA, et al
    Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27335.
    PubMed     Text format     Abstract available


  292. PARK JS, Koentjoro B, Klein C, Sue CM, et al
    Single heterozygous ATP13A2 mutations cause cellular dysfunction associated with Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27327.
    PubMed     Text format    


  293. SAMOTUS O, Parrent A, Jog M
    Spinal cord stimulation therapy for gait dysfunction in advanced Parkinson's disease patients.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.
    PubMed     Text format     Abstract available


  294. FAZIO P, Svenningsson P, Cselenyi Z, Halldin C, et al
    Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27316.
    PubMed     Text format     Abstract available


  295. BOUCA-MACHADO R, Lennaerts-Kats H, Bloem B, Ferreira JJ, et al
    Why palliative care applies to Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27309.
    PubMed     Text format    


  296. DAGAN M, Herman T, Harrison R, Zhou J, et al
    Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300.
    PubMed     Text format     Abstract available


  297. PALMA JA
    Autonomic dysfunction in Parkinson's disease and other synucleinopathies: Introduction to the series.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27347.
    PubMed     Text format    


  298. ABBASI N, Mohajer B, Abbasi S, Hasanabadi P, et al
    Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27284.
    PubMed     Text format     Abstract available


  299. MULAK A
    A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27304.
    PubMed     Text format    


  300. MAHLKNECHT P, Gasperi A, Djamshidian A, Kiechl S, et al
    Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27281.
    PubMed     Text format     Abstract available


  301. BAHIRAEE A, Ebrahimi R
    A noble pathological role for alpha-synuclein in triggering neurodegeneration of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27306.
    PubMed     Text format    


  302. CREED RB, Goldberg MS
    New developments in genetic rat models of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27296.
    PubMed     Text format     Abstract available


  303. WEINTRAUB D, Hamilton JL, Eberling J, Litvan I, et al
    At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27310.
    PubMed     Text format    


  304. LAGRAVINESE G, Pelosin E, Bonassi G, Carbone F, et al
    Gait initiation is influenced by emotion processing in Parkinson's disease patients with freezing.
    Mov Disord. 2018 Feb 2. doi: 10.1002/mds.27312.
    PubMed     Text format     Abstract available


  305. NAROS G, Grimm F, Weiss D, Gharabaghi A, et al
    Directional communication during movement execution interferes with tremor in Parkinson's disease.
    Mov Disord. 2018;33:251-261.
    PubMed     Text format     Abstract available


    January 2018
  306. NOYCE AJ, Dickson J, Rees RN, Bestwick JP, et al
    Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27282.
    PubMed     Text format     Abstract available


  307. MOREAU C, Duce JA, Rascol O, Devedjian JC, et al
    Iron as a therapeutic target for Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27275.
    PubMed     Text format    


  308. PAL G, Ouyang B, Verhagen L, Serrano G, et al
    Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27280.
    PubMed     Text format    


  309. CHEN V, Saez-Atienzar S
    A tango for two: Dopamine and alpha-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27248.
    PubMed     Text format    


  310. SAVICA R, Grossardt BR, Rocca WA, Bower JH, et al
    Parkinson disease with and without Dementia: A prevalence study and future projections.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27277.
    PubMed     Text format     Abstract available


  311. HIMMELBERG MM, West RJH, Wade AR, Elliott CJH, et al
    A perceptive plus in Parkinson's disease.
    Mov Disord. 2018 Jan 14. doi: 10.1002/mds.27240.
    PubMed     Text format    


  312. KIM IY, O'Reilly EJ, Hughes KC, Gao X, et al
    Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.
    Mov Disord. 2018 Jan 10. doi: 10.1002/mds.27279.
    PubMed     Text format     Abstract available


  313. GARCIA-SANZ P, Moratalla R
    The importance of cholesterol in Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27251.
    PubMed     Text format    


  314. GAO Y, Wilson GR, Stephenson SEM, Bozaoglu K, et al
    The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27270.
    PubMed     Text format     Abstract available


  315. AHMADI NS
    Mutant parkin-induced parkinsonism from an electrical point of view: Abnormal excitatory response to dopamine resolved after substitution.
    Mov Disord. 2018;33:71.
    PubMed     Text format    


  316. FASANO A, Lang AE, Espay AJ
    What is "essential" about essential tremor? A diagnostic placeholder.
    Mov Disord. 2018;33:58-61.
    PubMed     Text format    


  317. ALBANESE A
    Classifying tremor: Language matters.
    Mov Disord. 2018;33:3-4.
    PubMed     Text format    


  318. SCHEPERJANS F
    The prodromal microbiome.
    Mov Disord. 2018;33:5-7.
    PubMed     Text format    


    December 2017
  319. MEROLA A, Romagnolo A, Rosso M, Suri R, et al
    Autonomic dysfunction in Parkinson's disease: A prospective cohort study.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27268.
    PubMed     Text format     Abstract available


  320. MARRINAN SL, Otiker T, Vasist LS, Gibson RA, et al
    A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27259.
    PubMed     Text format     Abstract available


  321. BOWER JH, Grossardt BR, Rocca WA, Savica R, et al
    Prevalence of and indications for antipsychotic use in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27256.
    PubMed     Text format     Abstract available


  322. LIU Z, Tang B
    Novel Parkinson's disease risk loci identified through a meta-analysis of genome-wide association studies.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27276.
    PubMed     Text format    


  323. BOUTHOUR W, Wegrzyk J, Momjian S, Peron J, et al
    Short pulse width in subthalamic stimulation in Parkinson's disease: a randomized, double-blind study.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27265.
    PubMed     Text format     Abstract available


  324. ROOSEN DA, Singleton AB
    Leucine rich repeat kinase knockout (LRRK KO) mouse model: Linking pathological hallmarks of inherited and sporadic Parkinson's disease.
    Mov Disord. 2017 Dec 19. doi: 10.1002/mds.27267.
    PubMed     Text format    


  325. PICCONI B, Hernandez LF, Obeso JA, Calabresi P, et al
    Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Mov Disord. 2017 Dec 8. doi: 10.1002/mds.27261.
    PubMed     Text format     Abstract available


  326. GOLDMAN JG, Andrews H, Amara A, Naito A, et al
    Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27232.
    PubMed     Text format     Abstract available


  327. KIEBURTZ K, Katz R, Olanow CW
    New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27220.
    PubMed     Text format    


  328. FERNANDES HJR
    Beyond the lysosome: Cholesterol role on endoplasmic reticulum and lipid droplets in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27249.
    PubMed     Text format    


  329. PADMANABHAN S, Burke RE
    Induction of axon growth in the adult brain: A new approach to restoration in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27209.
    PubMed     Text format    


    November 2017
  330. LOZANO CS, Tam J, Lozano AM
    The changing landscape of surgery for Parkinson's Disease.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27228.
    PubMed     Text format     Abstract available


  331. BHATIA KP, Bain P, Bajaj N, Elble RJ, et al
    Consensus Statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27121.
    PubMed     Text format     Abstract available


  332. SVENSSON E, Henderson VW, Szepligeti S, Stokholm MG, et al
    Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study.
    Mov Disord. 2017 Nov 29. doi: 10.1002/mds.27253.
    PubMed     Text format     Abstract available


  333. BUARD I, Sciacca DM, Martin CS, Rogers S, et al
    Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Nov 27. doi: 10.1002/mds.27246.
    PubMed     Text format    


  334. TROPEA TF, Xie SX, Rick J, Chahine LM, et al
    APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27204.
    PubMed     Text format     Abstract available


  335. KOHSAKA M, Oeda T, Umemura A, Tomita S, et al
    Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27243.
    PubMed     Text format    


  336. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27233.
    PubMed     Text format     Abstract available


  337. KULIKOVSKAJA L, Seibler P
    Dopamine oxidation mediates a time-dependent pathological cascade in Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27262.
    PubMed     Text format    


  338. STEIGERWALD F, Timmermann L, Kuhn A, Schnitzler A, et al
    Pulse duration settings in subthalamic stimulation for Parkinson's disease.
    Mov Disord. 2017 Nov 22. doi: 10.1002/mds.27238.
    PubMed     Text format     Abstract available


  339. POCHARD C, Leclair-Visonneau L, Coron E, Neunlist M, et al
    Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27237.
    PubMed     Text format    


  340. WEAVER FM, Stroupe KT, Smith B, Gonzalez B, et al
    Survival in patients with Parkinson's disease after deep brain stimulation or medical management.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27235.
    PubMed     Text format     Abstract available


  341. DAFSARI HS, Reker P, Stalinski L, Silverdale M, et al
    Quality of life outcomes after subthalamic stimulation in Parkinson's disease depends on age.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27222.
    PubMed     Text format     Abstract available


  342. SYRKIN-NIKOLAU J, Neuville R, O'Day J, Anidi C, et al
    Coordinated reset vibrotactile stimulation shows prolonged improvement in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27223.
    PubMed     Text format    


  343. ELAHI E
    PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability.
    Mov Disord. 2017 Nov 16. doi: 10.1002/mds.27126.
    PubMed     Text format    


  344. HELMICH RC
    The cerebral basis of Parkinsonian tremor: A network perspective.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27224.
    PubMed     Text format     Abstract available


  345. GOETZ CG
    Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years?
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27214.
    PubMed     Text format    


  346. ARNALDI D, De Carli F, Fama F, Brugnolo A, et al
    Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27190.
    PubMed     Text format     Abstract available


  347. SCHNEIDER SA, Alcalay RN
    Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
    Mov Disord. 2017;32:1504-1523.
    PubMed     Text format     Abstract available


  348. SCHAPIRA AH
    What would James Parkinson think? A virtual dialogue on factors influencing the development of Parkinson's disease.
    Mov Disord. 2017;32:1499-1500.
    PubMed     Text format    


    October 2017
  349. SOHAIL S, Yu L, Schneider JA, Bennett DA, et al
    Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27200.
    PubMed     Text format     Abstract available


  350. LI W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, et al
    11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27183.
    PubMed     Text format     Abstract available


  351. METEREAU E, Beaudoin-Gobert M, Duperrier S, Thobois S, et al
    Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
    Mov Disord. 2017 Oct 27. doi: 10.1002/mds.27201.
    PubMed     Text format     Abstract available


  352. FASANO A, Canning CG, Hausdorff JM, Lord S, et al
    Falls in Parkinson's disease: A complex and evolving picture.
    Mov Disord. 2017 Oct 25. doi: 10.1002/mds.27195.
    PubMed     Text format     Abstract available


  353. WEINTRAUB D, Chahine LM, Hawkins KA, Siderowf A, et al
    Cognition and the course of prodromal Parkinson's disease.
    Mov Disord. 2017 Oct 24. doi: 10.1002/mds.27189.
    PubMed     Text format     Abstract available


  354. FENGLER S, Liepelt-Scarfone I, Brockmann K, Schaffer E, et al
    Cognitive changes in prodromal Parkinson's disease: A review.
    Mov Disord. 2017 Oct 5. doi: 10.1002/mds.27135.
    PubMed     Text format     Abstract available


  355. ASCHERIO A, Schwarzschild MA
    Dietary antioxidants and Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27194.
    PubMed     Text format    


  356. SAEED U, Masellis M
    Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27171.
    PubMed     Text format    


  357. MACLEOD AD, Dalen I, Tysnes OB, Larsen JP, et al
    Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27177.
    PubMed     Text format     Abstract available


  358. WEIL RS, Pappa K, Schade RN, Schrag AE, et al
    The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27176.
    PubMed     Text format    


  359. FORD KJ, Joop A, Memon RA, Wood KH, et al
    Pedestrian safety in patients with Parkinson's disease: A case-control study.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27124.
    PubMed     Text format     Abstract available


  360. STANDAERT DG
    What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.
    Mov Disord. 2017;32:1341-1342.
    PubMed     Text format    


    September 2017
  361. THEVATHASAN W, Debu B, Aziz T, Bloem BR, et al
    Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review.
    Mov Disord. 2017 Sep 28. doi: 10.1002/mds.27098.
    PubMed     Text format     Abstract available


  362. BIUNDO R, Weis L, Abbruzzese G, Calandra-Buonaura G, et al
    Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Mov Disord. 2017 Sep 27. doi: 10.1002/mds.27181.
    PubMed     Text format     Abstract available


  363. TESSITORE A, De Micco R, Giordano A, di Nardo F, et al
    Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27139.
    PubMed     Text format     Abstract available


  364. ROSE SJ, Harrast P, Donsante C, Fan X, et al
    Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27169.
    PubMed     Text format     Abstract available


  365. FULLARD ME, Xie SX, Marek K, Stern M, et al
    Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.
    Mov Disord. 2017 Sep 14. doi: 10.1002/mds.27127.
    PubMed     Text format     Abstract available


  366. SAME K, Ghazi Sherbaf F, Aarabi MH
    New link between Parkinson's and Alzheimer's: Research uncovers the role of mutant leucine rich repeat kinase 2 and amyloid precursor protein.
    Mov Disord. 2017 Sep 13. doi: 10.1002/mds.27170.
    PubMed     Text format    


  367. FRISALDI E, Carlino E, Zibetti M, Barbiani D, et al
    The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
    Mov Disord. 2017 Sep 12. doi: 10.1002/mds.27142.
    PubMed     Text format     Abstract available


  368. YANG F, Wolk A, Hakansson N, Pedersen NL, et al
    Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27120.
    PubMed     Text format     Abstract available


  369. HAN W, Sapkota S, Camicioli R, Dixon RA, et al
    Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27173.
    PubMed     Text format     Abstract available


  370. GHAHREMANI A, Chen R
    Deep brain stimulation modulates the shape of cortical beta oscillations in Parkinson's disease.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27144.
    PubMed     Text format    


  371. EUSEBI P, Giannandrea D, Biscetti L, Abraha I, et al
    Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27110.
    PubMed     Text format     Abstract available


  372. BRAKEDAL B, Flones I, Reiter SF, Torkildsen O, et al
    Glitazone use associated with reduced risk of Parkinson's disease.
    Mov Disord. 2017 Sep 1. doi: 10.1002/mds.27128.
    PubMed     Text format     Abstract available


  373. OBESO JA, Stamelou M, Goetz CG, Poewe W, et al
    Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.
    Mov Disord. 2017;32:1264-1310.
    PubMed     Text format     Abstract available



  374. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative
    Mov Disord. 2017;32:e1-e19.
    PubMed     Text format    


    August 2017
  375. TREZZI JP, Galozzi S, Jaeger C, Barkovits K, et al
    Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27132.
    PubMed     Text format     Abstract available


  376. HEINTZ-BUSCHART A, Pandey U, Wicke T, Sixel-Doring F, et al
    The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27105.
    PubMed     Text format     Abstract available


  377. TURCANO P, Mielke MM, Josephs KA, Bower JH, et al
    Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27125.
    PubMed     Text format     Abstract available


  378. PARNETTI L, Paciotti S, Eusebi P, Dardis A, et al
    Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27136.
    PubMed     Text format     Abstract available


  379. BORGHAMMER P
    How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27138.
    PubMed     Text format     Abstract available


  380. OERTEL W, Eggert K, Pahwa R, Tanner CM, et al
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Mov Disord. 2017 Aug 21. doi: 10.1002/mds.27131.
    PubMed     Text format     Abstract available


  381. CHAUDHURI KR, Jenner P
    Two hundred years since James Parkinson's essay on the shaking palsy-Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27104.
    PubMed     Text format    


  382. POLLARD EE
    Where we've gone "right" in the Parkinson's community.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27076.
    PubMed     Text format    


  383. ROCCA WA
    The future burden of Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27114.
    PubMed     Text format    


  384. MIYAUE N, Tada S, Ando R, Yabe H, et al
    cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27109.
    PubMed     Text format    


  385. BANDRES-CIGA S, Cookson MR
    Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder?
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27116.
    PubMed     Text format    


  386. GARCIA-SANZ P, Orgaz L, Bueno-Gil G, Espadas I, et al
    N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
    Mov Disord. 2017 Aug 5. doi: 10.1002/mds.27119.
    PubMed     Text format     Abstract available


  387. LILL CM, Klein C
    What would Dr. James Parkinson think today? The role of genetics in Parkinson's disease.
    Mov Disord. 2017;32:1115-1116.
    PubMed     Text format    


    July 2017
  388. CHUNG SJ, Shin JH, Cho KH, Lee Y, et al
    Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27106.
    PubMed     Text format     Abstract available


  389. DELPONT B, Lhommee E, Klinger H, Schmitt E, et al
    Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27101.
    PubMed     Text format     Abstract available


  390. OFORI E, Krismer F, Burciu RG, Pasternak O, et al
    Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Mov Disord. 2017 Jul 17. doi: 10.1002/mds.27100.
    PubMed     Text format     Abstract available


  391. THIBAULT L, Rascol O, Corvol JC, Ferreira J, et al
    New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
    Mov Disord. 2017 Jul 13. doi: 10.1002/mds.27055.
    PubMed     Text format    


  392. PAYAMI H
    The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27099.
    PubMed     Text format     Abstract available


  393. KOJOVIC M, Kassavetis P, Parees I, Georgiev D, et al
    Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27091.
    PubMed     Text format    


  394. CORREIA GUEDES L, Reimao S, Paulino P, Nunes RG, et al
    Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27083.
    PubMed     Text format    


  395. HEINZEL S, Bernhard FP, Roeben B, Nussbaum S, et al
    Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27062.
    PubMed     Text format    


  396. SAEZ-ATIENZAR S, Singleton AB
    Parkinson Disease and Clathrin Coat Dynamics at Synapses, Why Not?
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27097.
    PubMed     Text format    


  397. SONG N, Wang W, Jia F, Du X, et al
    Assessments of plasma ghrelin levels in the early stages of parkinson's disease.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27095.
    PubMed     Text format     Abstract available


  398. HUANG P, Tan YY, Liu DQ, Herzallah MM, et al
    Motor-symptom laterality affects acquisition in Parkinson's disease: A cognitive and functional magnetic resonance imaging study.
    Mov Disord. 2017;32:1047-1055.
    PubMed     Text format     Abstract available


  399. OBESO JA, Trenkwalder C
    What would Dr. James Parkinson think today? The 21st Annual Congress of the International Parkinson's disease and movement disorders society.
    Mov Disord. 2017;32:951-954.
    PubMed     Text format    


    June 2017
  400. ZABETIAN CP, Mata IF
    LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Mov Disord. 2017 Jun 28. doi: 10.1002/mds.27081.
    PubMed     Text format    


  401. GOETZ CG, Stebbins GT, Chung KA, Nicholas AP, et al
    Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
    Mov Disord. 2017 Jun 24. doi: 10.1002/mds.27092.
    PubMed     Text format    


  402. LHOMMEE E, Boyer F, Wack M, Pelissier P, et al
    Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation.
    Mov Disord. 2017 Jun 23. doi: 10.1002/mds.27065.
    PubMed     Text format     Abstract available


  403. STEINER LA, Neumann WJ, Staub-Bartelt F, Herz DM, et al
    Subthalamic beta dynamics mirror Parkinsonian bradykinesia months after neurostimulator implantation.
    Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27068.
    PubMed     Text format     Abstract available


  404. CHOTIBUT T, Meadows S, Kasanga EA, McInnis T, et al
    Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27077.
    PubMed     Text format     Abstract available


  405. BONET-PONCE L, Singleton AB
    Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27078.
    PubMed     Text format    


  406. CLAASSEN DO, Stark AJ, Spears CA, Petersen KJ, et al
    Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors.
    Mov Disord. 2017 Jun 19. doi: 10.1002/mds.27047.
    PubMed     Text format     Abstract available


  407. PELOSI A
    Cell-specific alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
    Mov Disord. 2017 Jun 16. doi: 10.1002/mds.27071.
    PubMed     Text format    


  408. FRIEDMAN JH
    Drug-induced parkinsonism.
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27050.
    PubMed     Text format    


  409. ROCCA WA, Savica R, Grossardt BR
    Response to Letter by Friedman on "Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study".
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27051.
    PubMed     Text format    


  410. HOOGLAND J, Boel JA, de Bie RMA, Geskus RB, et al
    Mild cognitive impairment as a risk factor for Parkinson's disease dementia.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27002.
    PubMed     Text format     Abstract available


  411. TITOVA N, Chaudhuri KR
    Personalized medicine in Parkinson's disease: Time to be precise.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27027.
    PubMed     Text format    


  412. LARSSON SC, Singleton AB, Nalls MA, Richards JB, et al
    No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study.
    Mov Disord. 2017 Jun 8. doi: 10.1002/mds.27069.
    PubMed     Text format     Abstract available


  413. ROSSI A, Berger K, Chen H, Leslie D, et al
    Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27063.
    PubMed     Text format     Abstract available


  414. KASSUBEK J, Huppertz HJ, Hoglinger GU
    Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27057.
    PubMed     Text format    


  415. KUMAR A
    Reprogramming the striatal stars: A new treatment option for Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27067.
    PubMed     Text format    


  416. QUATTRONE A, Nigro S
    MRI measures of brainstem in Parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27056.
    PubMed     Text format    


  417. MAHLKNECHT P, Akram H, Georgiev D, Tripoliti E, et al
    Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27042.
    PubMed     Text format     Abstract available


  418. PINA-FUENTES D, Little S, Oterdoom M, Neal S, et al
    Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.26959.
    PubMed     Text format    



  419. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2017;32 Suppl 2:S1-S1079.
    PubMed     Text format    


  420. MANDEMAKERS W, Quadri M, Stamelou M, Bonifati V, et al
    TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27061.
    PubMed     Text format     Abstract available


  421. PEREZ-SORIANO A, Arena JE, Dinelle K, Miao Q, et al
    PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27029.
    PubMed     Text format     Abstract available


  422. AKRAM H, Wu C, Hyam J, Foltynie T, et al
    l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease.
    Mov Disord. 2017;32:874-883.
    PubMed     Text format     Abstract available


  423. VAILLANCOURT DE
    What Would Dr. James Parkinson Think Today? Tau and Other Imaging Possibilities in Parkinson's Disease.
    Mov Disord. 2017;32:805-806.
    PubMed     Text format    


  424. LENKA A, Pal PK
    "Miro" in Parkinson's disease: Here, there, everywhere!
    Mov Disord. 2017;32:839.
    PubMed     Text format    


    May 2017
  425. NG ASL, Tan EK
    Linking statins and lipids in Parkinson's disease.
    Mov Disord. 2017 May 27. doi: 10.1002/mds.27053.
    PubMed     Text format    


  426. DELGADO-ALVARADO M, Gago B, Gorostidi A, Jimenez-Urbieta H, et al
    Tau/alpha-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27001.
    PubMed     Text format     Abstract available


  427. KIM YJ, Jeon J, Shin J, Kim NY, et al
    Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27019.
    PubMed     Text format     Abstract available


  428. COLLIER TJ, Kanaan NM, Kordower JH
    Aging and Parkinson's disease: Different sides of the same coin?
    Mov Disord. 2017 May 18. doi: 10.1002/mds.27037.
    PubMed     Text format     Abstract available


  429. PILOTTO A, Heinzel S, Suenkel U, Lerche S, et al
    Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.
    Mov Disord. 2017 May 16. doi: 10.1002/mds.27035.
    PubMed     Text format     Abstract available


  430. SHAHMOON S, Jahanshahi M
    Optimizing psychosocial adjustment after deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Mov Disord. 2017 May 15. doi: 10.1002/mds.27032.
    PubMed     Text format    


  431. YADAV AP, Nicolelis MAL
    Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.
    Mov Disord. 2017 May 12. doi: 10.1002/mds.27033.
    PubMed     Text format     Abstract available


  432. MEROLA A, Rosso M, Romagnolo A, Comi C, et al
    Peripheral neuropathy as marker of severe Parkinson's disease phenotype.
    Mov Disord. 2017 May 8. doi: 10.1002/mds.27025.
    PubMed     Text format    


  433. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force.
    Mov Disord. 2017;32:724-725.
    PubMed     Text format    


  434. POSTUMA RB
    Sleep Disorders and RBD: What Would James Parkinson Think?
    Mov Disord. 2017;32:705-707.
    PubMed     Text format    


  435. ST LOUIS EK, Boeve AR, Boeve BF
    REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
    Mov Disord. 2017;32:645-658.
    PubMed     Text format     Abstract available


  436. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings.
    Mov Disord. 2017;32:722-723.
    PubMed     Text format    


  437. MCKENNA D, Peever J
    Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder.
    Mov Disord. 2017;32:636-644.
    PubMed     Text format     Abstract available


  438. HOGL B, Stefani A
    Restless legs syndrome and periodic leg movements in patients with movement disorders: Specific considerations.
    Mov Disord. 2017;32:669-681.
    PubMed     Text format     Abstract available


    April 2017
  439. STROUWEN C, Molenaar EALM, Munks L, Keus SHJ, et al
    Training dual tasks together or apart in Parkinson's disease: Results from the DUALITY trial.
    Mov Disord. 2017 Apr 25. doi: 10.1002/mds.27014.
    PubMed     Text format     Abstract available


  440. DIEZ H, Cortes-Saladelafont E, Ormazabal A, Marmiese AF, et al
    Severe infantile parkinsonism because of a de novo mutation on DLP1 mitochondrial-peroxisomal protein.
    Mov Disord. 2017 Apr 24. doi: 10.1002/mds.27021.
    PubMed     Text format    


  441. OLSZEWSKA DA, Lynch T
    Nature's Parkin experiment: Nix-a novel protective mechanism in Parkinson's disease.
    Mov Disord. 2017 Apr 22. doi: 10.1002/mds.27015.
    PubMed     Text format    


  442. BEAULIEU ML, Muller MLTM, Bohnen NI
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26994.
    PubMed     Text format    


  443. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.27009.
    PubMed     Text format    


  444. FERESHTEHNEJAD SM, Montplaisir JY, Pelletier A, Gagnon JF, et al
    Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26989.
    PubMed     Text format     Abstract available


  445. BURTE F, Houghton D, Lowes H, Pyle A, et al
    metabolic profiling of Parkinson's disease and mild cognitive impairment.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26992.
    PubMed     Text format     Abstract available


  446. KOOLE M, Laere KV, Ahmad R, Ceccarini J, et al
    Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.27005.
    PubMed     Text format    


  447. CACACE F, Mineo D, Viscomi MT, Latagliata EC, et al
    Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26982.
    PubMed     Text format     Abstract available


  448. YANG X, An R, Xi J, Zheng J, et al
    Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26996.
    PubMed     Text format    


  449. OLANOW CW, Kieburtz K, Leinonen M, Elmer L, et al
    A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26941.
    PubMed     Text format     Abstract available


  450. LIU G, Sterling NW, Kong L, Lewis MM, et al
    Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.27006.
    PubMed     Text format     Abstract available


  451. KORDOWER JH
    What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Mov Disord. 2017;32:483-484.
    PubMed     Text format    


  452. BALCK A, Klein C
    Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection.
    Mov Disord. 2017;32:527.
    PubMed     Text format    


    March 2017
  453. ORGAZ L, Gil GB
    Modulating mitochondrial pyruvate carrier: A promising therapeutic target in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26962.
    PubMed     Text format    


  454. FOX SH, Metman LV, Nutt JG, Brodsky M, et al
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26976.
    PubMed     Text format     Abstract available


  455. PONT-SUNYER C, Tolosa E, Caspell-Garcia C, Coffey C, et al
    The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26964.
    PubMed     Text format     Abstract available


  456. LEHERICY S, Vaillancourt DE, Seppi K, Monchi O, et al
    The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26968.
    PubMed     Text format     Abstract available


  457. BARICHELLA M, Cereda E, Cassani E, Frazzitta G, et al
    A focus on Rome III criteria for the assessment of constipation in Parkinson's disease.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26974.
    PubMed     Text format    


  458. XU T, Wang S, Lalchandani RR, Ding JB, et al
    Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26938.
    PubMed     Text format     Abstract available


  459. MEROLA A, Romagnolo A, Comi C, Rosso M, et al
    Prevalence and burden of dysautonomia in advanced Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26970.
    PubMed     Text format    


  460. F HERNANDEZ L, Castela I, Ruiz-DeDiego I, Obeso JA, et al
    Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26947.
    PubMed     Text format     Abstract available


  461. ANDERKOVA L, Barton M, Rektorova I
    Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26956.
    PubMed     Text format     Abstract available


  462. PAGANO G, Niccolini F, Yousaf T, Wilson H, et al
    Urinary dysfunction in early de novo patients with Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26967.
    PubMed     Text format    


  463. PEREZ XA, Zhang D, Bordia T, Quik M, et al
    Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26955.
    PubMed     Text format     Abstract available


  464. HANSEN AK, Damholdt MF, Fedorova TD, Knudsen K, et al
    In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26961.
    PubMed     Text format     Abstract available


  465. GIANNOCCARO MP, La Morgia C, Rizzo G, Carelli V, et al
    Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.
    Mov Disord. 2017 Mar 2. doi: 10.1002/mds.26966.
    PubMed     Text format     Abstract available


  466. MARRAS C
    What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life.
    Mov Disord. 2017;32:364-365.
    PubMed     Text format    


    February 2017
  467. ESPAY AJ, Schwarzschild MA, Tanner CM, Fernandez HH, et al
    Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Mov Disord. 2017 Feb 24. doi: 10.1002/mds.26913.
    PubMed     Text format     Abstract available


  468. HORVATH K, Aschermann Z, Kovacs M, Makkos A, et al
    Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale.
    Mov Disord. 2017 Feb 20. doi: 10.1002/mds.26960.
    PubMed     Text format     Abstract available


  469. MIKI Y, Yoshizawa T, Morohashi S, Seino Y, et al
    Neuropathology of PARK14 is identical to idiopathic Parkinson's disease.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26952.
    PubMed     Text format    


  470. ROSA M, Arlotti M, Marceglia S, Cogiamanian F, et al
    Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26953.
    PubMed     Text format    


  471. HILL-BURNS EM, Debelius JW, Morton JT, Wissemann WT, et al
    Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Mov Disord. 2017 Feb 14. doi: 10.1002/mds.26942.
    PubMed     Text format     Abstract available


  472. PONZO V, Di Lorenzo F, Brusa L, Schirinzi T, et al
    Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26931.
    PubMed     Text format     Abstract available


  473. ANSARI M, Sobhani S
    Impaired glutamate release in GPe astrocytes, disinhibits striatopallidal transmission in Parkinsonian mice.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26943.
    PubMed     Text format    


  474. GALLEA C, Ewenczyk C, Degos B, Welter ML, et al
    Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders.
    Mov Disord. 2017 Feb 6. doi: 10.1002/mds.26923.
    PubMed     Text format     Abstract available


  475. DEL REY NL, Blesa J
    Parkinson's disease: Oh my gut!
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26933.
    PubMed     Text format    


  476. MAHLKNECHT P, Krismer F, Poewe W, Seppi K, et al
    Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26932.
    PubMed     Text format     Abstract available


  477. MOLLER L, Kassubek J, Sudmeyer M, Hilker R, et al
    Manual MRI morphometry in Parkinsonian syndromes.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26921.
    PubMed     Text format     Abstract available


  478. STRAFELLA AP, Bohnen NI, Perlmutter JS, Eidelberg D, et al
    Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26907.
    PubMed     Text format     Abstract available


  479. OLANOW CW, Kordower JH
    Targeting alpha-Synuclein as a therapy for Parkinson's disease: The battle begins.
    Mov Disord. 2017;32:203-207.
    PubMed     Text format    


  480. ALBIN RL
    What would Dr. James Parkinson think today? II. Neuroimaging in Parkinson's disease.
    Mov Disord. 2017;32:179-180.
    PubMed     Text format    


  481. EBRAHIMI R, Sobhani S, Abbastabar M
    Whether the dissociation between toxicity and alpha-synuclein inclusion will be a possible therapy for Parkinson's disease or not?
    Mov Disord. 2017;32:210.
    PubMed     Text format    



  482. Abstracts of the 1st Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2017;32 Suppl 1:S1-S90.
    PubMed     Text format    


    January 2017
  483. MORBERG BM, Malling AS, Jensen BR, Gredal O, et al
    Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26927.
    PubMed     Text format    


  484. VIDENOVIC A
    Management of sleep disorders in Parkinson's disease and multiple system atrophy.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26918.
    PubMed     Text format     Abstract available


  485. NOYCE AJ, R'Bibo L, Peress L, Bestwick JP, et al
    PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26898.
    PubMed     Text format     Abstract available


  486. QUADRI M, Breedveld GJ, Chang HC, Yeh TH, et al
    Mutations in TMEM230 are not a common cause of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26900.
    PubMed     Text format    


  487. MOHASEL S, Sobhani S
    The role of amyloidogenic proteins as a meeting point of type 2 diabetes and Parkinson's disease pathways.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26897.
    PubMed     Text format    


  488. VISANJI NP, Bhudhikanok GS, Mestre TA, Ghate T, et al
    Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26896.
    PubMed     Text format     Abstract available


  489. SCHNEIDER SA, Bras J
    Mouse models of kufor-rakeb disease link Parkinson's disease closer to neuronal ceroid lipofuscinosis, suggesting lysosomal dysfunction as shared mechanism.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26899.
    PubMed     Text format    


  490. BESTE C, Muckschel M, Rosales R, Domingo A, et al
    Striosomal dysfunction affects behavioral adaptation but not impulsivity-Evidence from X-linked dystonia-parkinsonism.
    Mov Disord. 2017 Jan 6. doi: 10.1002/mds.26895.
    PubMed     Text format     Abstract available


  491. SPATARO N, Roca-Umbert A, Cervera-Carles L, Valles M, et al
    Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients.
    Mov Disord. 2017;32:165-169.
    PubMed     Text format     Abstract available


  492. ZHANG M, Xi Z, Misquitta K, Sato C, et al
    C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism.
    Mov Disord. 2017;32:158-162.
    PubMed     Text format     Abstract available


  493. HARIZ M, Obeso JA
    What Would Dr. James Parkinson Think Today? I. The Role of Functional Neurosurgery for Parkinson's Disease.
    Mov Disord. 2017;32:2-4.
    PubMed     Text format    


  494. BLUMENFELD Z, Koop MM, Prieto TE, Shreve LA, et al
    Sixty-hertz stimulation improves bradykinesia and amplifies subthalamic low-frequency oscillations.
    Mov Disord. 2017;32:80-88.
    PubMed     Text format     Abstract available


  495. CHO H, Choi JY, Hwang MS, Lee SH, et al
    Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy.
    Mov Disord. 2017;32:134-140.
    PubMed     Text format     Abstract available


  496. VALSKY D, Marmor-Levin O, Deffains M, Eitan R, et al
    Stop! border ahead: Automatic detection of subthalamic exit during deep brain stimulation surgery.
    Mov Disord. 2017;32:70-79.
    PubMed     Text format     Abstract available


    December 2016
  497. LANGLEY J, Huddleston DE, Sedlacik J, Boelmans K, et al
    Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26883.
    PubMed     Text format     Abstract available


  498. RAHMANI F, Kamalian A, Aarabi MH
    New evidence comes to light: How is alpha-synuclein aggregation related to mitochondrial protein import in Parkinson's disease?
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26889.
    PubMed     Text format    


  499. BLAUWENDRAAT C, Nalls MA, Federoff M, Pletnikova O, et al
    ADORA1 mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26886.
    PubMed     Text format    


  500. SENEK M, Nielsen EI, Nyholm D
    Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26855.
    PubMed     Text format     Abstract available


  501. PAL GD, Ouyang B, Serrano G, Shill HA, et al
    Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26882.
    PubMed     Text format     Abstract available


  502. DZAMKO N, Gysbers AM, Bandopadhyay R, Bolliger MF, et al
    LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26892.
    PubMed     Text format     Abstract available


  503. MARTINEZ-MARTIN P
    What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26885.
    PubMed     Text format     Abstract available


  504. GOETZ CG, Liu Y, Stebbins GT, Wang L, et al
    Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Mov Disord. 2016;31:1865-1873.
    PubMed     Text format     Abstract available


  505. WILLIS AW, Thibault DP, Schmidt PN, Dorsey ER, et al
    Hospital care for mental health and substance abuse conditions in Parkinson's disease.
    Mov Disord. 2016;31:1810-1819.
    PubMed     Text format     Abstract available


  506. SHI CH, Zhang SY, Yang ZH, Yang J, et al
    A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.
    Mov Disord. 2016;31:1905-1909.
    PubMed     Text format     Abstract available


    November 2016
  507. DE PABLO-FERNANDEZ E, Courtney R, Holton JL, Warner TT, et al
    Hypothalamic alpha-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease.
    Mov Disord. 2016 Nov 28. doi: 10.1002/mds.26868.
    PubMed     Text format    


  508. KNUDSEN K, Krogh K, Ostergaard K, Borghammer P, et al
    Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26866.
    PubMed     Text format     Abstract available


  509. PILLAS M, Selai C, Schrag A
    Rasch analysis of the carers quality of life questionnaire for parkinsonism.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26877.
    PubMed     Text format     Abstract available


  510. RAUSCHENDORF MA, Jost M, Stock F, Zimmer A, et al
    Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26876.
    PubMed     Text format    


  511. HE YC, Huang P, Li QQ, Sun Q, et al
    TMEM230 stop codon mutation is rare in parkinson's disease and essential tremor in eastern China.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26875.
    PubMed     Text format    


  512. POLITIS M, Sauerbier A, Loane C, Pavese N, et al
    Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
    Mov Disord. 2016 Nov 17. doi: 10.1002/mds.26848.
    PubMed     Text format     Abstract available


  513. GALIMBERTI D, Cioffi SM, Fenoglio C, Serpente M, et al
    Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26872.
    PubMed     Text format    


  514. FIFEL K
    Alterations of the circadian system in Parkinson's disease patients.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26865.
    PubMed     Text format     Abstract available


  515. ISOTALO J, Vahlberg T, Kaasinen V
    Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26862.
    PubMed     Text format    


  516. XIE T, Kang UJ
    Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26861.
    PubMed     Text format    


  517. GAARE JJ, Skeie GO, Tzoulis C, Larsen JP, et al
    Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26856.
    PubMed     Text format     Abstract available


  518. PINTO DE SOUZA C, Hamani C, Oliveira Souza C, Lopez Contreras WO, et al
    Spinal cord stimulation improves gait in patients with Parkinson's disease previously treated with deep brain stimulation.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26850.
    PubMed     Text format     Abstract available


  519. KLETTNER A, Tholey A, Wiegandt A, Richert E, et al
    Reduction of GAPDH in lenses of Parkinson's disease patients: A possible new biomarker.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26863.
    PubMed     Text format     Abstract available


  520. BEUDEL M, Oswal A, Jha A, Foltynie T, et al
    Oscillatory Beta Power Correlates With Akinesia-Rigidity in the Parkinsonian Subthalamic Nucleus.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26860.
    PubMed     Text format    


  521. DI BIASE L, Fasano A
    Reply to: Comments on recent viewpoint article by Lazzaro di Biase and Alfonso Fasano titled "Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?"
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26859.
    PubMed     Text format    


  522. NEUMANN WJ, Kuhn AA
    Subthalamic beta power-Unified Parkinson's disease rating scale III correlations require akinetic symptoms.
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26858.
    PubMed     Text format    


  523. SGAMBATO-FAURE V
    Control of the direct pathway by cholinergic interneurons is involved in parkinsonian motor symptoms.
    Mov Disord. 2016 Nov 2. doi: 10.1002/mds.26840.
    PubMed     Text format    


    October 2016
  524. FOO JN, Lee J, Tan LC, Liu J, et al
    Large 3-Mb deletions at 22q11.2 locus in parkinson's disease and schizophrenia.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26822.
    PubMed     Text format    


  525. HUGHES KC, Gao X, Kim IY, Rimm EB, et al
    Intake of antioxidant vitamins and risk of parkinson's disease.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26819.
    PubMed     Text format     Abstract available


  526. TINAZZI M, Geroin C, Gandolfi M, Smania N, et al
    Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26829.
    PubMed     Text format     Abstract available


  527. MANGESIUS S, Krismer F, Gizewski ER, Muller C, et al
    1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26823.
    PubMed     Text format    


  528. SAVICA R, Grossardt BR, Bower JH, Ahlskog JE, et al
    Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26839.
    PubMed     Text format     Abstract available


  529. TARSY D
    Addition of a virtual reality component to treadmill training to reduce fall risk in older adults, including individuals with Parkinson's disease.
    Mov Disord. 2016 Oct 19. doi: 10.1002/mds.26843.
    PubMed     Text format    


  530. KHODADADI H, Azcona LJ, Aghamollaii V, Omrani MD, et al
    PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26824.
    PubMed     Text format     Abstract available


  531. TROSTER AI, Jankovic J, Tagliati M, Peichel D, et al
    Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26827.
    PubMed     Text format     Abstract available


  532. PYLE A, Lowes H, Brennan R, Kurzawa-Akanbi M, et al
    Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26825.
    PubMed     Text format    


  533. BALINT B, Bhatia KP
    SLC39A14 mutations expand the spectrum of manganese transporter defects causing parkinsonism-dystonia.
    Mov Disord. 2016 Oct 14. doi: 10.1002/mds.26821.
    PubMed     Text format    


  534. KLEIN C, Lochte T, Delamonte SM, Braenne I, et al
    PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical Features and Neuropathology.
    Mov Disord. 2016 Oct 6. doi: 10.1002/mds.26814.
    PubMed     Text format    


  535. POLLI A, Weis L, Biundo R, Thacker M, et al
    Anatomical and functional correlates of persistent pain in parkinson's disease.
    Mov Disord. 2016 Oct 5. doi: 10.1002/mds.26826.
    PubMed     Text format     Abstract available


    September 2016
  536. PONS R, Kekou K, Antonellou R, Svingou M, et al
    Analysis of a founder mutation in the TH gene in a cohort of greek patients with Parkinson's disease.
    Mov Disord. 2016 Sep 26. doi: 10.1002/mds.26807.
    PubMed     Text format    


  537. SVENSSON E, Horvath-Puho E, Stokholm MG, Sorensen HT, et al
    Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26761.
    PubMed     Text format     Abstract available


  538. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naive cohort.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26742.
    PubMed     Text format     Abstract available


  539. WONG YC, Krainc D
    Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26802.
    PubMed     Text format     Abstract available


  540. KETT LR, Dauer WT
    Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26797.
    PubMed     Text format     Abstract available


  541. RIEDEL O
    Bringing light into the darkness: Dependence in Parkinson's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26795.
    PubMed     Text format    


  542. DELVAL A, Rambour M, Tard C, Dujardin K, et al
    Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26762.
    PubMed     Text format     Abstract available


    April 2016
  543. WEISS D, Herrmann S, Wang L, Schulte C, et al
    Alpha-synuclein gene variants may predict neurostimulation outcome.
    Mov Disord. 2016;31:601-3.
    PubMed     Text format    


  544. LAWTON M, Kasten M, May MT, Mollenhauer B, et al
    Validation of conversion between mini-mental state examination and montreal cognitive assessment.
    Mov Disord. 2016;31:593-6.
    PubMed     Text format     Abstract available


  545. LANG AE, Rodriguez RL, Boyd JT, Chouinard S, et al
    Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Mov Disord. 2016;31:538-46.
    PubMed     Text format     Abstract available


    March 2016
  546. MESTRE TA, Lang AE, Okun MS
    Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mov Disord. 2016;31:290-6.
    PubMed     Text format     Abstract available


  547. OROPESA-RUIZ JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, et al
    Low serum uric acid levels in progressive supranuclear palsy.
    Mov Disord. 2016;31:402-5.
    PubMed     Text format     Abstract available


  548. WILE DJ, Dinelle K, Vafai N, McKenzie J, et al
    A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
    Mov Disord. 2016;31:405-9.
    PubMed     Text format     Abstract available


  549. WALTER U, Muller JU, Rosche J, Kirsch M, et al
    Magnetic resonance-transcranial ultrasound fusion imaging: A novel tool for brain electrode location.
    Mov Disord. 2016;31:302-9.
    PubMed     Text format     Abstract available


    February 2016
  550. STEFANOVA N, Kordower JH, Wenning GK
    Preface.
    Mov Disord. 2016;31:151.
    PubMed     Text format    


  551. RICCIARDI L, Petrucci S, Di Giuda D, Serra L, et al
    The Contursi Family 20 Years Later: Intrafamilial Phenotypic Variability of the SNCA p.A53T Mutation.
    Mov Disord. 2016;31:257-8.
    PubMed     Text format    


  552. RUFFMANN C, Parkkinen L
    Gut Feelings About alpha-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?
    Mov Disord. 2016;31:193-202.
    PubMed     Text format     Abstract available


  553. CALO L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M, et al
    Synaptic failure and alpha-synuclein.
    Mov Disord. 2016;31:169-77.
    PubMed     Text format     Abstract available


  554. BERGSTROM AL, Kallunki P, Fog K
    Development of Passive Immunotherapies for Synucleinopathies.
    Mov Disord. 2016;31:203-13.
    PubMed     Text format     Abstract available


  555. VALERA E, Masliah E
    Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Mov Disord. 2016;31:225-34.
    PubMed     Text format     Abstract available


  556. MCCANN H, Cartwright H, Halliday GM
    Neuropathology of alpha-synuclein propagation and braak hypothesis.
    Mov Disord. 2016;31:152-60.
    PubMed     Text format     Abstract available


  557. SCHNEEBERGER A, Tierney L, Mandler M
    Active immunization therapies for Parkinson's disease and multiple system atrophy.
    Mov Disord. 2016;31:214-24.
    PubMed     Text format     Abstract available


    January 2016
  558. CARTA M, Cenci MA
    On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Mov Disord. 2016;31:149.
    PubMed     Text format    


  559. OLANOW CW, Poewe W
    Eldad Melamed 1942-2015: Ave atque--A memorial.
    Mov Disord. 2016;31:39-40.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: